

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 June 2004 (24.06.2004)

PCT

(10) International Publication Number
WO 2004/053157 A2

(51) International Patent Classification⁷: C12Q 1/68,
A01K 67/027, A61K 38/00, 39/00, 48/00

Paul [GB/US]; 376 Highland Avenue, Winchester, MA 01890 (US). CARPENTER, William, Twitty [US/US]; 11018 Thistlebrook Court, Columbia, MD 21044 (US). ROBERTS, Rosalinda, Cusido [US/US]; 5985 Gales Lane, Columbia, MD 21045 (US). TAMMINGA, Carol, Ann [US/US]; 5510 Nakoma, Dallas, TX 75209 (US).

(21) International Application Number:
PCT/EP2003/014089

(74) Agent: GRUBB, Philip; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(22) International Filing Date:
11 December 2003 (11.12.2003)

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(25) Filing Language: English

(84) Designated States (regional): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(26) Publication Language: English

(71) Applicant (for all designated States except AT, US): NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(71) Applicant (for all designated States except US): UNIVERSITY OF MARYLAND [US/US]; 520 West Lombard Street, Baltimore, MD 21201 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BUXTON, Francis,

(71) Applicant (for all designated States except AT, US): NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(71) Applicant (for all designated States except US): UNIVERSITY OF MARYLAND [US/US]; 520 West Lombard Street, Baltimore, MD 21201 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BUXTON, Francis,

Published:
— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/053157 A2

(54) Title: METHODS FOR DIAGNOSING AND TREATING SCHIZOPHRENIA

(57) Abstract: The genes encoding SCYA2, GADD45B, S100A8, CDKN1A, IL1RL1, TGM2, MAFF, SERPINA3, GRO1, CD14, KIAA1075, CHI3L1, SERPINH1, MT1X, KIAA0620, TIMP1, NUMA1, DDT3 and TOB2, are upregulated in the anterior cingulate of schizophrenic patients compared to normal patients and as such are useful drug targets for schizophrenia. Methods of screening, diagnosing and treating schizophrenia based on these genes are provided. Transgenic nonhuman animals having increased copy number or increased expression levels of these genes are also provided. The transgenic nonhuman animals are used in methods for screening for potential therapeutic agents.

METHODS FOR DIAGNOSING AND TREATING SCHIZOPHRENIA

BACKGROUND

1. Field of the Invention

The present disclosure relates to genes correlated to schizophrenia and methods of using genes for diagnosis and treatment of schizophrenia.

2. Description of Related Art

Schizophrenia is a severe psychiatric disorder usually characterized by withdrawal from reality, illogical patterns of thinking, delusions and hallucinations, and accompanied in varying degrees by other emotional, behavioral, or intellectual disturbances. See Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, American Psychiatric Association, 273-315 (1994) (DSM-IV™). However, as stated therein, no single symptom is pathognomonic of schizophrenia; the diagnosis involves recognition of a constellation of signs and symptoms associated with impaired occupational or social functioning. Id. Some detectable physiological changes have been reported, e.g., neuropathological and imaging studies depicting anatomical alterations associated with the disease. Arnold et al., Acta Neuropathol. (Berl) 92, 217- 231 (1996); Harrison, Brain 122, 593-624 (1999). Certain cellular aberrations have been observed and biochemical and RNA analyses have demonstrated alterations in some neurotransmitter pathways and presynaptic components. Id.; Benes, Brain Res. Rev. 31, 251-269 (2000).

At beginning stages and even at more advanced stages, schizophrenia can involve subtle behavioral changes and subtle and/or undetectable changes at the cellular and/or molecular levels in nervous system structure and function. This lack of detectable neurological defect distinguishes schizophrenia from other well-defined neurological disorders in which anatomical or biochemical pathologies are clearly manifest. Thus, there is a need for non-subjective modalities for screening and diagnosis of schizophrenia. Moreover, identification of the causative defects and the

neuropathologies of schizophrenia are needed in order to enable clinicians to evaluate and prescribe appropriate courses of treatment to cure or ameliorate the symptoms of schizophrenia at early stages or when symptoms are obscured. Indeed, there are few effective therapies for the disease and its molecular basis is still not well understood.

Methods have been designed to survey alterations in mRNA expression in order to search for genes deregulated in various diseases and disorders. In organisms for which the complete genome is known, it is possible to analyze the transcripts of all genes within the cell. With other organisms, such as human, for which there is an increasing knowledge of the genome, it is possible to simultaneously monitor large numbers of genes within a cell. DNA microarray analysis is a technique that permits the quantitative measurement of the transcriptional expression of several thousand genes simultaneously. This technique permits one to generate profiles of gene expression patterns in both patients suffering from schizophrenia and control individuals. Accordingly, determination of abnormal levels of gene expression provides a signpost for therapeutic intervention.

Techniques for modifying RNA levels and activities involve ribozymes, antisense species, and RNA aptamers and small molecule promoter modulators. Ribozymes are RNAs capable of catalyzing RNA cleavage reactions, and some can be designed to specifically cleave a particular target mRNA. Ribozyme methods include exposing a cell to, inducing expression in a cell, etc. of such RNA ribozyme molecules. Activity of a target RNA (preferably mRNA) species, specifically its rate of translation, can be inhibited by the application of antisense nucleic acids. "Antisense" nucleic acids are nucleic acids capable of hybridizing to a sequence specific portion of the target RNA, e.g., its translation initiation region by virtue of some sequence that is complementary to a coding and/or non-coding region. The antisense nucleic acid can be oligonucleotides that are double-stranded or single-stranded, RNA or DNA or a modification or derivative thereof, which can be produced intracellularly by transcription of exogenous, introduced sequences in controllable quantities sufficient to perturb translation of the target RNA.

The above described techniques are emerging as an effective means for reducing the expression of specific gene products and may therefore prove to be uniquely useful in a number of therapeutic, diagnostic and research applications for the modulation of genes that are disregulated in schizophrenic patients.

We have previously discovered that three genes (decidual protein induced by progesterone (DEPP), adrenomedullin and cold shock domain protein A (cdsA)) are upregulated in schizophrenia. We have now surprisingly discovered that mRNA for nineteen other genes (disclosed in Table 1 herein) are similarly upregulated in samples from schizophrenic individuals. Thus, these genes can be used as novel drug targets for schizophrenia.

SUMMARY

In one aspect, a method for screening for schizophrenia in a population is provided which comprises determining, in members of the population, the magnitude of expression of a gene selected from the group consisting of those disclosed in Table 1 in a sample and comparing the magnitude of expression to a baseline magnitude of expression of the gene, wherein increased gene expression indicates the presence of schizophrenia. The sample may be taken from the brain, spinal cord, lymphatic fluid, blood, urine or feces.

In another aspect, a method for diagnosing schizophrenia in a host is provided which comprises determining the magnitude of expression of a gene selected from the group consisting of those disclosed in Table 1 in a sample and comparing the magnitude of expression to a baseline magnitude of expression of the gene, wherein increased gene expression indicates the presence of schizophrenia.

In another aspect, a method for treating schizophrenia in a host is provided which comprises lowering expression of a gene selected from the group consisting of those disclosed in Table 1 by administering to the host an expression lowering amount of antisense oligonucleotide.

In another aspect, a method for treating schizophrenia in a host is provided which comprises lowering expression of a gene selected from the group consisting of the genes disclosed in Table 1 by administering to the host an expression lowering amount of a ribozyme which cleaves RNA associated with expression of the gene.

In another aspect, a method for treating schizophrenia in a host is provided which comprises lowering expression of a gene selected from the group consisting of those disclosed in Table 1 by administering one or more nucleic acid molecules designed to promote triple helix formation with said gene.

In another aspect, a method for treating schizophrenia is provided which comprises reducing the amount of a gene disclosed in Table 1 in a patient by administering an effective amount of an antibody against the protein or proteins selected.

In another aspect, a method for treating schizophrenia is provided which comprises reducing the amount of a gene disclosed in Table 1 in a patient by administering an effective amount of a RNAi against the gene or genes selected.

In another aspect, a method of screening for compounds which are useful in the treatment of schizophrenia is provided which comprises operatively linking a reporter gene which expresses a detectable protein to a regulatory sequence for a gene selected from the group consisting of those disclosed in Table 1 to produce a reporter construct, transfected a cell with the reporter construct, exposing the transfected cell to a test compound, and comparing the level of expression of the reporter gene after exposure to the test compound to the level of expression before exposure to the test compound, wherein a lower level of expression after exposure is indicative of a compound useful for the treatment of schizophrenia.

In another aspect, a transgenic nonhuman animal is provided whose genome stably comprises an increased copy number of a gene selected from the group

consisting of those disclosed in Table 1 wherein the gene is expressed at higher than baseline levels and the animal exhibits abnormal behavior.

In another aspect, a transgenic animal is provided whose genome stably comprises a gene selected from the group consisting of those disclosed in Table 1 wherein expression of the gene is enhanced by at least one alteration in regulatory sequences of the gene such that the gene is expressed at higher than baseline levels and the animal exhibits abnormal behavior.

In another aspect, a transgenic nonhuman knockout animal is provided whose genome stably comprises a homozygous disruption in one or more genes selected from the group consisting of those disclosed in Table 1 wherein said homozygous disruption prevents the expression of the gene, and wherein said homozygous disruption results in the transgenic knockout animal exhibiting decreased expression levels of the one or more genes as compared to a wild-type animal.

In another aspect, the invention provides a method to screen for therapeutic agents that modulate symptoms of schizophrenia by administering a candidate compound to the transgenic nonhuman animals disclosed above and determining the effect of the compound on symptoms associated with schizophrenia.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

In practicing the present invention, many conventional techniques in molecular biology are used. These techniques are well known and are explained in, for example, Current Protocols in Molecular Biology, Volumes I, II, and III, 1997 (F. M. Ausubel ed.); Sambrook et al., 1989, Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; DNA Cloning: A Practical Approach, Volumes I and II, 1985 (D. N. Glover ed.); Oligonucleotide Synthesis, 1984 (M. L. Gait ed.); Nucleic Acid Hybridization, 1985, (Hames and Higgins); Transcription and Translation, 1984 (Hames and Higgins eds.); Animal Cell Culture, 1986 (R. I. Freshney ed.); Immobilized Cells and Enzymes, 1986 (IRL Press); Perbal, 1984, A Practical Guide to Molecular Cloning; the series, Methods in Enzymology (Academic Press, Inc.); Gene Transfer Vectors for Mammalian Cells, 1987 (J. H. Miller and M. P. Calos eds., Cold Spring Harbor Laboratory); and Methods in Enzymology Vol. 154 and Vol. 155 (Wu and Grossman, and Wu, eds., respectively).

As used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to the "antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

As used herein, the definition of a "schizophrenic disease or disorder" encompasses the characterization of this disease as described in the references cited above .

"Nucleic acid sequence", as used herein, refers to an oligonucleotide, nucleotide or polynucleotide, and fragments or portions thereof, and to DNA or RNA

of genomic or synthetic origin that may be single or double stranded, and represent the sense or antisense strand.

The term "antisense" as used herein, refers to nucleotide sequences which are complementary to a specific DNA or RNA sequence. The term "antisense strand" is used in reference to a nucleic acid strand that is complementary to the "sense" strand. Antisense molecules may be produced by any method, including synthesis by ligating the gene(s) of interest in a reverse orientation to a viral promoter which permits the synthesis of a complementary strand. Once introduced into a cell, this transcribed strand combines natural sequences produced by the cell to form duplexes. These duplexes then block either the further transcription or translation. The designation "negative" is sometimes used in reference to the antisense strand, and "positive" is sometimes used in reference to the sense strand.

As contemplated herein, antisense oligonucleotides, triple helix DNA, RNA aptamers, RNAi, ribozymes and double or single stranded RNA are directed to a nucleic acid sequence of a gene disclosed in Table 1 such that the nucleotide sequence of the gene chosen will produce gene-specific inhibition of gene expression. For example, knowledge of the target gene nucleotide sequence may be used to design an antisense molecule which gives strongest hybridization to the mRNA. Similarly, ribozymes can be synthesized to recognize specific nucleotide sequences and cleave them (Cech. J. Amer. Med Assn. 260:3030 (1988)). Techniques for the design of such molecules for use in targeted inhibition of gene expression is well known to one of skill in the art.

As used herein, the term "antibody" refers to intact molecules as well as fragments thereof, such as Fa, F(ab')₂, and Fv, which are capable of binding the epitopic determinant. Antibodies that bind polypeptides of interest can be prepared using intact polypeptides or fragments containing small peptides of interest as the immunizing antigen. The polypeptides or peptides used to immunize an animal can be derived from the translation of RNA or synthesized chemically, and can be conjugated to a carrier protein, if desired. Commonly used carriers that are

chemically coupled to peptides include bovine serum albumin and thyroglobulin. The coupled peptide is then used to immunize an animal (e.g., a mouse, a rat or a rabbit).

The term "humanized antibody" as used herein, refers to antibody molecules in which amino acids have been replaced in the non-antigen binding regions in order to more closely resemble a human antibody, while still retaining the original binding ability.

A "therapeutically effective amount" is the amount of drug sufficient to treat and /or ameliorate the pathological effects of chronic pain, including but not limited to, hyperalgesia.

The term "therapeutic agent" as used herein describes any molecule, e.g. protein, carbohydrate, metal or organic compound, with the capability of affecting the molecular and clinical phenomena associated with schizophrenia. Generally a plurality of assay mixtures may be run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e. at zero concentration or below the level of detection.

"Subject" refers to any human or nonhuman organism.

The present disclosure is based on the surprising discovery that nineteen genes are associated with schizophrenia in affected individuals. More particularly, these genes are upregulated in the anterior cingulate of schizophrenic patients as compared to normal patients. The complete list of these genes is disclosed below in Table 1.

Table 1

GENE NAME	ABBREVIATION USED HEREIN
Small inducible cytokineA2	SCYA2
Growth arrest and DNA-damage-inducible beta	GADD45B

S100 calcium binding protein A8	S100A8
Cyclin-dependent kinase inhibitor 1A p21/Cip1	CDKN1A
Interleukin 1receptor-like 1	IL1RL1
Transglutaminase	TGM2
V-maf musculo aponeurotic fibrosarcoma oncogene homolog F	MAFF
Serine or cysteine proteinase inhibitor clade A member 3	SERPINA3
GRO1 oncogene melanoma growth stimulating activityalpha	GRO1
CD14 antigen	CD14
Tensin 2	KIAA1075
Chitinase 3-like 1, cartilage glycoprotein-39	CHI3L1
Serine or cysteine proteinase inhibitor clade H	SERPINH1
Metallothionein 1X	MT1X
KIAA0620 protein	KIAA0620
Tissue inhibitor of metalloproteinase 1	TIMP1
Nuclear mitotic apparatus protein 1	NUMA1
DNA-damage-inducible transcript 3	DDIT3
Transducer of ERBB2	TOB2

Accordingly, methods for the diagnosis, screening and evaluation of schizophrenia are provided in accordance with the present invention. For example, assays for determination of increased levels of expression of these genes are provided. Moreover, nucleic acid molecules encoding these genes can be used as diagnostic hybridization probes or used to design primers for diagnostic PCR analysis for the identification of gene mutations, allelic variations and regulatory defects in these genes. As used herein, "diagnosis" is intended to generally apply to individuals while "screening" is generally applicable to populations or individuals. The invention also encompasses antibodies to the products of the genes disclosed in

Table 1 that can be used to decrease available plasma levels of these proteins, as well as nucleotide sequences that can be used to inhibit gene expression (e.g., antisense, RNAi and ribozyme molecules), and gene or regulatory sequence binding or replacement constructs designed to reduce or enhance gene expression (e.g., triple helix forming moieties or expression constructs that place the genes under the control of a strong promoter system).

The surprising expression characteristics of the genes disclosed in Table 1 were uncovered by examination of post mortem anterior cingulate samples from schizophrenic and normal subjects. Samples possessing high quality RNA were utilized for further study. Those skilled in the art are familiar with techniques which may be utilized to determine expression levels. For example, reverse transcriptase assays or DNA microarray analysis can be performed utilizing gene chip technology. Differentially expressed genes can be identified using a number of methods developed in accordance with established principles. Statistical significance of the expression differences between groups of samples may be determined utilizing the t-test, ANOVA or non-parametric tests. In accordance with the present invention, some genes were found to be upregulated in schizophrenic patients while others were found to be downregulated compared to baseline or normal levels. The terms "normal" and "baseline" are used interchangeably herein. Baseline levels are defined using conventional statistical techniques in connection with an analysis of a general population of non-schizophrenics. See, e.g., Example 1 herein. It should be understood, in general, that methods not otherwise specified herein are conducted in accordance with generally accepted principles known to those skilled in the art.

Quantitative rtPCR (Q-PCR) may be conducted on the same samples used for the expression level analysis described above. After conversion of RNA to cDNA using reverse transcriptase, although any conventional PCR technique can be utilized, a preferred technique may be based on the TaqMan® technique (Perkin Elmer Corp., Foster City, CA). In conventional PCR assays, oligonucleotide primers are designed complementary to the 5' and 3'ends of a DNA sequence of interest. During thermal cycling, DNA is heat denatured. The sample is then brought to

annealing and extension temperatures in which the primers bind their specific complements and are extended by the addition of nucleotide tri-phosphates by Taq polymerase. With repeated thermal cycling, the amount of template DNA is amplified. The presence of a dye, such as SybrGreenTM, that fluoresces strongly when bound to DNA, allows the real time monitoring of total amount of DNA product in the tube. By measuring this signal, the amplified product can be quantified. The threshold cycle (C_T) at which the fluorescent signal is measurably different from the background noise is an accurate measure of the starting amount of cDNA in the tube and hence RNA in the sample. This method allows the quantitation of genes in a complex RNA by targeting specific DNAs. Of the genes initially identified by microarray analysis to be differentially expressed in schizophrenic patients, twenty two, decidual protein induced by progesterone (DEPP), csdA ,adrenomedullin as well as those disclosed herein in Table 1, were shown to be differentially regulated in the original set of RNA samples.

In one aspect, a method of screening for schizophrenia in a population is provided which includes determining, in members of the population, the magnitude of expression of a gene selected from those disclosed in Table 1 in a sample and comparing the magnitude of expression to a baseline magnitude of expression of the gene, wherein increased gene expression indicates the presence of schizophrenia.

In another aspect, a method for diagnosing schizophrenia in a host is provided which includes determining the magnitude of expression of a gene consisting of those disclosed in Table 1 in a sample and comparing the magnitude of expression to a baseline magnitude of expression of the gene, wherein increased gene expression indicates the presence of schizophrenia. In either of the above screening or diagnosing aspects, the sample may be taken, for example, from the brain, spinal cord, lymphatic fluid, blood, urine or feces.

There are numerous techniques known to those with skill in the art to measure gene expression in a sample. For example, RNA from a cell type or tissue known, or suspected, to express a gene disclosed in Table 1 , such as brain, may be isolated

and tested utilizing hybridization or PCR techniques such as are described above. The isolated RNA can be derived directly from a biological sample from a patient.

In one embodiment of such a detection scheme, a cDNA molecule is synthesized from an RNA molecule of interest (e.g., by reverse transcription of the RNA molecule into cDNA). A sequence within the cDNA is then used as the template for a nucleic acid amplification reaction, such as a PCR amplification reaction, or the like. The nucleic acid reagents used as synthesis initiation reagents (e.g., primers) in the reverse transcription and nucleic acid amplification steps of this method are chosen from among the genes disclosed in Table 1. Those skilled in the art are familiar with techniques for designing and obtaining suitable primers. See, e.g., Table 2 in Example 2 below. The preferred lengths of such nucleic acid reagents are at least 9-30 nucleotides. For detection of the amplified product, the nucleic acid amplification may be performed using radioactively or non-radioactively labeled nucleotides. Alternatively, enough amplified product may be made such that the product may be visualized by standard ethidium bromide staining or by utilizing any other suitable nucleic acid staining method.

Additionally, it is possible to perform such gene expression assays "in situ", i.e., directly upon tissue sections (fixed and/or frozen) of patient tissue obtained from biopsies or resections, such that no nucleic acid purification is necessary. Nucleic acid reagents such as those described above may be used as probes and/or primers for such in situ procedures. Alternatively, if a sufficient quantity of the appropriate cells can be obtained, standard Northern analysis can be performed to determine the level of mRNA expression of a gene disclosed in Table 1.

Regardless of the method used to quantify the expression of a gene or genes disclosed in Table 1, the level of expression in a subject of undefined etiology is compared to a known normal expression level. If the expression level of one, or more than one, of these genes is elevated above the normal or baseline level by about 25%, a diagnosis of schizophrenia may be made or confirmed. Determination of higher levels may be indicative of the severity of the disease.

As demonstrated by the Examples below, one technique for establishing baseline levels may involve real time quantitative PCR. Those skilled in the art are familiar with numerous techniques which may be utilized to test sample populations to obtain statistically sound results. For example, in carrying out this technique, a sample from a population of normal individuals is selected. The sample should be sufficiently diverse in terms of age, sex, social status, geographical distribution, previous drug and medical histories, etc. and of sufficient size to provide a meaningful statistical value. Thus, expression of a gene disclosed in Table 1 is measured in the sample of interest which defines distribution in the normal population. Baseline levels are then assigned. A set of diseased subjects is also assayed to determine validity of the test by comparing results of the diseased sample to those of the normal sample.

In accordance with the present invention, symptoms of schizophrenia associated with upregulation of a gene or genes disclosed in Table 1 may be ameliorated by decreasing the level of any one or more of these genes or gene product activity by using appropriately designed gene sequences in conjunction with well-known antisense, gene "knock-out," ribozyme, RNAi and/or triple helix methods to decrease the level of expression of any one or more genes disclosed in Table 1.

Among the compounds that may exhibit the ability to modulate the activity, expression or synthesis of genes disclosed in Table 1 including the ability to ameliorate the symptoms of schizophrenia associated with overexpression of any one or more of these genes, are antisense, ribozyme, RNAi and triple helix molecules. Such molecules may be designed to reduce or inhibit either unimpaired, or if appropriate, mutant target gene activity. Techniques for the production and use of such molecules are well known to those skilled in the art.

Antisense RNA and DNA molecules act to block the translation of mRNA by hybridizing to target mRNA and preventing protein translation. Antisense approaches involve the design of oligonucleotides that are complementary to a target gene

mRNA. The antisense oligonucleotides will bind to the complementary target gene mRNA transcripts and prevent translation. Absolute complementarity, although preferred, is not required.

A sequence "complementary" to a portion of an RNA, as referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double-stranded antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with an RNA it may contain and still form a stable duplex (or triplex, as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

In one embodiment, oligonucleotides complementary to coding or non-coding regions of a gene disclosed in Table 1 could be used in an antisense approach to inhibit translation of the endogenous mRNA for any one or more of these genes. mRNA. Based upon the sequences presented herein, or upon allelic or homologous genomic and/or DNA sequences, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention. Antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In certain preferred aspects the oligonucleotide length is from about 8 to about 30 nucleotides.

Suitable antisense oligonucleotides herein encompass modified oligonucleotides which may exhibit enhanced stability, targeting or which otherwise exhibit enhanced therapeutic effectiveness. Examples of modified oligonucleotides include those where (1) at least two nucleotides are covalently linked via a synthetic internucleoside linkage (i.e., a linkage other than a phosphodiester linkage between the 5' end of one nucleotide and the 3' end of another nucleotide) and/or (2) a

chemical group not normally associated with nucleic acids has been covalently attached to the oligonucleotide. Examples of synthetic internucleoside linkages are phosphorothioates, alkylphosphonates, phosphorodithioates, phosphate esters, alkylphosphonothioates, phosphoramidates, carbamates, phosphate triesters, acetamidates, peptides, and carboxymethyl esters. Modified oligonucleotides may also have covalently modified bases and/or sugars. For example, oligonucleotides having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified oligonucleotides may include a 2'-O-alkylated ribose group. In addition, modified oligonucleotides may include sugars such as arabinose instead of ribose. Modified oligonucleotides also can include base analogs such as C-5 propyne modified bases.

Antisense oligonucleotides may be synthesized by standard techniques known in the art, e.g., by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein, et al. (1988, *Nucl. Acids Res.* 16, 3209); methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin, et al., 1988, *Proc. Natl. Acad. Sci. U.S.A.* 85, 7448-7451), etc.

While antisense nucleotides complementary to the target gene coding region sequence could be used, those complementary to the transcribed, untranslated region are most preferred. A preferred site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene. Those with skill in the art are well aware of various suitable initiation or termination codons in both eukaryotes and prokaryotes.

Antisense molecules may be delivered to cells that express the target gene *in vivo*. A number of methods have been developed for delivering antisense DNA or RNA to cells; e.g., antisense molecules can be injected directly into the tissue site, or modified antisense molecules, designed to target the desired cells (e.g., antisense

linked to peptides or antibodies that specifically bind receptors or antigens expressed on the target cell surface) can be administered systemically. A preferred technique involves constructing a vector which incorporates a strong promoter to provide high expression and good yield of antisense oligonucleotides at the target site. The use of such a construct to transfect target cells in the patient results in the transcription of sufficient amounts of single stranded RNAs that will form complementary base pairs with the endogenous target gene transcripts and thereby prevent translation of the target gene mRNA. For example, a vector can be introduced such that it is taken up by a cell and directs the transcription of an antisense RNA. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods known to those in the art. Vectors can be, e.g., plasmid, viral, or others typically used for replication and expression in mammalian cells. It should be understood that expression of the sequence encoding the antisense RNA can be by any promoter known in the art to act in mammalian, preferably human cells. Such promoters can be inducible or constitutive. Any type of plasmid, cosmid, YAC, BAC or viral vector can be used to prepare the recombinant DNA construct which can be introduced directly into the tissue site. Alternatively, viral vectors can be used that selectively infect the desired tissue, in which case administration may be accomplished by another route (e.g., systemically).

Ribozyme molecules designed to catalytically cleave target gene mRNA transcripts can also be used to prevent or reduce translation of mRNA of any one or more genes disclosed in Table 1 herein and, therefore, expression of target gene product. (See, e.g., PCT International Publication W090/11364, published Oct. 4, 1990; Sarver, et al., 1990, *Science* 247, 1222-1225). Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by an endonucleolytic cleavage event. The composition of ribozyme molecules must include one or more sequences complementary to the target gene mRNA, and must include the well known catalytic

sequence responsible for mRNA cleavage. For this sequence, see, e.g., U.S. Pat. No. 5,093,246, incorporated herein by reference.

Ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy target gene mRNAs. For example, hammerhead ribozymes may be utilized to cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5'-UG-3'. The construction and production of hammerhead ribozymes is well known in the art. Preferably, the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the target gene mRNA, i.e., to increase efficiency and minimize the intracellular accumulation of non-functional protein fragments. Suitable ribozymes also include RNA endoribonucleases such as the one that occurs naturally in *Tetrahymena thermophila* (known as the IVS, or L-19 IVS RNA). This type of ribozymes have an eight base pair active site which hybridizes to a target RNA sequence to effect cleavage of the target RNA.

As in the antisense approach, the ribozymes can be composed of modified oligonucleotides (e.g., for improved stability, targeting, etc.) and should be delivered to cells that express the target gene *in vivo*. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous gene messages and inhibit translation. Because ribozymes, unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

Alternatively, endogenous expression of any one of more genes disclosed in Table 1 can be reduced by targeting deoxyribonucleotide sequences complementary to the regulatory region of the target genes (i.e., the target gene promoter and/or enhancers) to form triple helical structures that prevent transcription of the target gene in target cells in the body. Nucleic acid molecules to be used in triplex helix formation for the inhibition of transcription should be single stranded and composed

of deoxynucleotides. The base composition of these oligonucleotides must be designed to promote triple helix formation via Hoogsteen base pairing rules, which generally require sizeable stretches of either purines or pyrimidines to be present on one strand of a duplex. Nucleotide sequences may be pyrimidine-based, which will result in TAT and CGC⁺ triplets across the three associated strands of the resulting triple helix. The pyrimidine-rich molecules provide base complementarity to a purine-rich region of a single strand of the duplex in a parallel orientation to that strand. In addition, nucleic acid molecules may be chosen that are purine-rich, for example, contain a stretch of G residues. These molecules will form a triple helix with a DNA duplex that is rich in GC pairs, in which the majority of the purine residues are located on a single strand of the targeted duplex, resulting in GGC triplets across the three strands in the triplex.

Alternatively, the potential sequences that can be targeted for triple helix formation may be increased by creating a so-called "switchback" nucleic acid molecule. Switchback molecules are synthesized in an alternating 5'-3', 3'-5' manner, such that they base pair with first one strand of a duplex and then the other, eliminating the necessity for a sizeable stretch of either purines or pyrimidines to be present on one strand of a duplex.

RNA aptamers can also be introduced into or expressed in a cell to modify RNA abundance or activity. RNA aptamers are specific RNA ligands for proteins, such as for Tat and Rev RNA (Good et al., 1997, Gene Therapy 4: 45-54) that can specifically inhibit their translation. In addition, gene specific inhibition of gene expression may also be achieved using conventional double or single stranded RNA technologies. A description of such technology may be found in WO 99/32619 which is hereby incorporated by reference in its entirety. In addition, siRNA technology has also proven useful as a means to inhibit gene expression (Cullen, BR Nat. Immunol. 2002 Jul;3(7):597-9; J Martinez et al., Cell 2002 Sept. 6;110(5):563).

Anti-sense RNA and DNA, ribozyme, RNAi, RNA aptamer and triple helix molecules described herein may be prepared by any method known in the art for the

synthesis of DNA and RNA molecules, as discussed above. These include techniques for chemically synthesizing oligodeoxyribonucleotides and oligoribonucleotides well known in the art such as for example solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding the antisense RNA molecule. Such DNA sequences may be incorporated into a wide variety of vectors that incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.

A method of modulating the activity of a protein encoded by a gene disclosed in Table 1 to treat schizophrenia is provided comprising exposing neutralizing antibodies to said proteins. By providing for controlled exposure to such antibodies, protein abundances/activities can be controllably modified. For example, antibodies to suitable epitopes on protein surfaces may decrease the abundance, and thereby indirectly decrease the activity, of the wild-type active form of a protein encoded by a gene disclosed in Table 1 by aggregating active forms into complexes with less or minimal activity as compared to the wild-type unaggregated wild-type form. Alternatively, , antibodies may directly decrease protein activity by, e.g., interacting directly with active sites or by blocking access of substrates to active site. In either case, antibodies can be raised against specific protein species and their effects screened. The effects of the antibodies can be assayed and suitable antibodies selected that lower the target protein species concentration and/or activity. Such assays involve introducing antibodies into a cell or surrounding media, and assaying the concentration of the wild-type amount or activities of the target protein by standard means (such as immunoassays) known in the art. The net activity of the wild-type form can be assayed by assay means appropriate to the known activity of the target protein.

Antibodies can be introduced into cells in numerous ways, including, for example, microinjection of antibodies into a cell (Morgan et al., 1988, Immunology

Today 9:84-86) or transforming hybridoma mRNA encoding a desired antibody into a cell (Burke et al., 1984, Cell 36:847-858). In a further technique, recombinant antibodies can be engineered and ectopically expressed in a wide variety of non-lymphoid cell types to bind to target proteins as well as to block target protein activities. Preferably, expression of the antibody is under control of a controllable promoter, such as the Tet promoter. A first step is the selection of a particular monoclonal antibody with appropriate specificity to the target protein. Then sequences encoding the variable regions of the selected antibody can be cloned into various engineered antibody formats, including, for example, whole antibody, Fab fragments, Fv fragments, single chain Fv fragments (VH and VL regions united by a peptide linker) ("ScFv" fragments), diabodies (two associated ScFv fragments with different specificities), and so forth. Intracellularly expressed antibodies of the various formats can be targeted into cellular compartments by expressing them as fusions with the various known intracellular leader sequences.

Methods for the production of antibodies capable of specifically recognizing one or more Table 1 gene product epitopes or epitopes of conserved variants or peptide fragments of the proteins encoded by the genes disclosed in Table 1 are well known in the art. Such antibodies may include, but are not limited to, polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')₂ fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above.

Such antibodies may also be used, for example, in the detection of a Table 1 gene product in an biological sample and may, therefore, be utilized as part of a diagnostic or prognostic technique whereby patients may be tested for abnormal levels of any one or more of said gene products, and/or for the presence of abnormal forms of such gene products. Such antibodies may also be utilized in conjunction with, for example, compound screening schemes, for the evaluation of the effect of test compounds on any one or more of said gene product levels and/or activity.

For the production of antibodies against any one or more of the gene products disclosed herein various host animals may be immunized by injection with a Table 1 gene product, or a portion thereof. Such host animals may include, but are not limited to, rabbits, mice, goats, chickens and rats, to name but a few. Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*.

Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of animals immunized with an antigen, such as a Table 1 gene product, or an antigenic functional derivative thereof. For the production of polyclonal antibodies, host animals such as those described above, may be immunized by injection with a Table 1 gene product supplemented with adjuvants as described above.

Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, may be obtained by any technique that provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique of Kohler and Milstein, (1975, *Nature* 256, 495-497; and U.S. Pat. No. 4,376,110), the human B-cell hybridoma technique (Kosbor et al., 1983, *Immunology Today* 4, 72; Cole et al., 1983, *Proc. Natl. Acad. Sci. USA* 80, 2026-2030), and the EBV-hybridoma technique (Cole et al., 1985, *Monoclonal Antibodies And Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96). Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the mAb may be cultivated in vitro or in vivo.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison, et al., 1984, *Proc. Natl. Acad. Sci.*, 81, 6851-6855; Neuberger, et al., 1984,

Nature 312, 604-608; Takeda, et al., 1985, Nature, 314, 452-454) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region. Techniques have also been developed for the production of humanized antibodies. (See, e.g., Queen, U.S. Pat. No. 5,585,089.). An immunoglobulin light or heavy chain variable region consists of a "framework" region interrupted by three hypervariable regions, referred to as complementarity determining regions (CDRs). The extent of the framework region and CDRs have been precisely defined (see, e.g., "Sequences of Proteins of Immunological Interest", Kabat, E. et al., U.S. Department of Health and Human Services (1983)). Briefly, humanized antibodies are antibody molecules from non-human species having one or more CDRs from the non-human species and a framework region from a human immunoglobulin molecule. Alternatively, techniques described for the production of single chain antibodies (U.S. Pat. No. 4,946,778; Bird, 1988, Science 242, 423-426; Huston, et al., 1988, Proc. Natl. Acad. Sci. USA 85, 5879-5883; and Ward, et al., 1989, Nature 334, 544-546) can be adapted to produce single chain antibodies against any one or more of the proteins disclosed herein. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.

Antibody fragments that recognize specific epitopes may be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')₂ fragments, which can be produced by pepsin digestion of the antibody molecule and the Fab fragments, which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed (Huse, et al., 1989, Science, 246, 1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

Antibodies, or fragments of antibodies, such as those described, above, may be used to quantitatively or qualitatively detect the presence of any one or more

Table 1 gene product or conserved variants or peptide fragments thereof. This can be accomplished, for example, by immunofluorescence techniques employing a fluorescently labeled antibody coupled with light microscopic, flow cytometric, or fluorometric detection.

The antibodies (or fragments thereof) useful in the present invention may be employed histologically, as in immunofluorescence or immunoelectron microscopy, for in situ detection of any one or more Table 1 gene product, conserved variants or peptide fragments thereof. In situ detection may be accomplished by removing a histological specimen from a patient, and applying thereto a labeled antibody that binds to a polypeptide encoded by a gene disclosed in Table 1.. The antibody (or fragment) is preferably applied by overlaying the labeled antibody (or fragment) onto a biological sample. Through the use of such a procedure, it is possible to determine not only the presence of any one or more of said polypeptide, conserved variant or peptide fragment, but also its distribution in the examined tissue. Using the present invention, those of ordinary skill will readily recognize that any of a wide variety of histological methods (such as staining procedures) can be modified in order to achieve in situ detection the product of a gene disclosed in Table 1

Immunoassays for a product of a gene disclosed in Table 1 conserved variants, or peptide fragments thereof will typically comprise incubating a sample, such as a biological fluid, a tissue extract, freshly harvested cells, or lysates of cells in the presence of a detectably labeled antibody capable of identifying said gene product, conserved variant or peptide fragments thereof, and detecting the bound antibody by any of a number of techniques well-known in the art. The biological sample may be brought in contact with and immobilized onto a solid phase support or carrier, such as nitrocellulose, that is capable of immobilizing cells, cell particles or soluble proteins. The support may then be washed with suitable buffers followed by treatment with the detectably labeled protein appropriate specific antibodies. The solid phase support may then be washed with the buffer a second time to remove unbound antibody. The amount of bound label on the solid support may then be detected by conventional means.

One of the ways in which specific antibodies can be detectably labeled is by linking the same to an enzyme, such as for use in an enzyme immunoassay (EIA). The enzyme, which is bound to the antibody, will react with an appropriate substrate, preferably a chromogenic substrate, in such a manner as to produce a chemical moiety that can be detected, for example, by spectrophotometric, fluorimetric or by visual means. Enzymes that can be used to detectably label the antibody are well known. The detection can be accomplished by colorimetric methods that employ a chromogenic substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards. Detection may also be accomplished using any of a variety of other immunoassays. For example, by radioactively labeling the antibodies or antibody fragments, it is possible to detect any one or more proteins encoded by the genes disclosed in Table 1 through the use of a radioimmunoassay (RIA). The radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or by autoradiography. It is also possible to label the antibody with a fluorescent compound. When the fluorescently labeled antibody is exposed to light of the proper wavelength, its presence can then be detected due to fluorescence. Among the most commonly used fluorescent labeling compounds are green fluorescent protein, fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine. The antibody can also be detectably labeled using fluorescence emitting metals such as ¹⁵²Eu, or others of the lanthanide series. These metals can be attached to the antibody using such metal chelating groups as diethylenetriaminepentacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA). The antibody also can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester. Likewise, a bioluminescent compound may be used to label the antibody of the present invention. Bioluminescence is a type of chemiluminescence found in biological systems in

which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling include luciferin, luciferase and aequorin.

The present invention contemplates production of animal models that have abnormal expression levels of any one or more genes disclosed in Table 1 to study the effects of increased or decreased levels of these proteins on such animals. Such animals provide test subjects for determining the effects of therapeutic or potentially therapeutic compounds on schizophrenia. Accordingly, Table 1 gene products can be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, guinea pigs, pigs, mini-pigs, goats, sheep, and non-human primates, e.g., baboons, monkeys, and chimpanzees may be used to generate these transgenic animals. The term "transgenic," as used herein, refers to animals expressing any one or more Table 1 gene sequence from a different species (e.g., mice expressing human gene sequences), as well as animals that have been genetically engineered to overexpress endogenous (i.e., same species) gene sequences or animals that have been genetically engineered to no longer express endogenous gene sequences (i.e., "knockout" animals), and their progeny.

Any technique known in the art may be used to introduce genes into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Hoppe and Wagner, 1989, U.S. Pat. No. 4,873,191); retrovirus mediated gene transfer into germ lines (Van der Putten, et al., 1985, Proc. Natl. Acad. Sci., USA 82, 6148-6152); gene targeting in embryonic stem cells (Thompson, et al., 1989, Cell 56, 313-321); electroporation of embryos (Lo, 1983, Mol. Cell. Biol. 3, 1803-1814); and sperm-mediated gene transfer (Lavitrano et al., 1989, Cell 57, 717-723) (For a review of such techniques, see Gordon, 1989, Transgenic Animals, Intl. Rev. Cytol. 115, 171-229). Any technique known in the art may be used to produce transgenic animal clones containing a transgene, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic,

fetal or adult cells induced to quiescence (Campbell, et al., 1996, *Nature* 380, 64-66; Wilmut, et al., 1997, *Nature* 385, 810-813).

The present invention provides for transgenic animals that carry a transgene in all their cells, as well as animals that carry the transgene in some, but not all their cells, i.e., mosaic animals. The transgene may be integrated as a single transgene or in concatamers, e.g., head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko, et al., 1992, *Proc. Natl. Acad. Sci. USA* 89, 6232-6236). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu, et al., 1994, *Science* 265, 103-106. The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

As mentioned above, transgenic knockout animals are also provided herein. In such transgenic animals expression of any one or more genes disclosed in Table 1 is undetectable or insignificant. Any technique known in the art may be used to produce such transgenic knockout animals. This may be achieved by a variety of mechanisms, e.g., alteration of any or all of the Table 1 genes by, e.g., introduction of a disruption of the appropriate coding sequences, e.g., insertion of one or more stop codons, insertion of a DNA fragment, etc., deletion of regulatory or coding sequence, substitution of stop codons for coding sequence, etc. The transgenic animals may be either homozygous or heterozygous for the alteration. A functional

knock-out may also be achieved by the introduction of an anti-sense construct that blocks expression of the native genes. Knockouts also include conditional knockouts such as where alteration of the target gene occurs upon exposure of the animal to a substance that promotes target gene alteration, introduction of an enzyme that promotes recombination at the target gene site, or other method for directing the target gene alteration postnatally.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to assay whether integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques described above and those that include but are not limited to Northern blot analysis of tissue samples obtained from the animal, in situ hybridization analysis, and RT-PCR (reverse transcriptase PCR). Samples of gene-expressing tissue, may also be evaluated immunocytochemically using antibodies specific for the transgene product of interest.

Through use of the subject transgenic animals or cells derived therefrom, one can identify ligands or substrates that modulate phenomena associated with schizophrenia, e.g., behavioral phenomena. A wide variety of assays may be used for this purpose, including behavioral studies, determination of the localization of drugs after administration and the like. Depending on the particular assay, whole animals may be used, or cells derived therefrom. Cells may be freshly isolated from an animal, or may be immortalized in culture. Cells of particular interest are derived from neural tissue.

Candidate therapeutic agents encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 50 and less than about 2,500 daltons. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine,

carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate therapeutic agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate therapeutic agents are also found among biomolecules including, but not limited to: peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof.

As mentioned above, antibodies specific for proteins encoded by the genes disclosed in Table 1 may be used in screening immunoassays, particularly to detect the level of such gene product in a cell or sample. The number of cells in a sample will generally be at least about 10^3 , usually at least 10^4 more usually at least about 10^5 . The cells may be dissociated, in the case of solid tissues, or tissue sections may be analyzed. Alternatively a lysate of the cells may be prepared. For example, detection may utilize staining of cells or histological sections, performed in accordance with conventional methods. The antibodies of interest are added to the cell sample, and incubated for a period of time sufficient to allow binding to the epitope, usually at least about 10 minutes. The antibody may be labeled with radioisotopes, enzymes, fluorescers, chemiluminescers, or other labels for direct detection. Alternatively, a second stage antibody or reagent is used to amplify the signal. Such reagents are well known in the art. For example, the primary antibody may be conjugated to biotin, with horseradish peroxidase-conjugated avidin added as a second stage reagent. Final detection uses a substrate that undergoes a color change in the presence of the peroxidase. The absence or presence of antibody binding may be determined by various methods, including flow cytometry of dissociated cells, microscopy, radiography, scintillation counting, etc.

A number of assays are known in the art for determining the effect of a drug on animal behavior and other phenomena associated with schizophrenia. Some examples are provided, although it will be understood by one of skill in the art that many other assays may also be used. The subject animals may be used by themselves, or in combination with control animals.

The screen using the transgenic animals of the invention can employ any phenomena associated with schizophrenia that can be readily assessed in an animal model. The screening for schizophrenia can include assessment of phenomena including, but not limited to: 1) analysis of molecular markers (e.g., levels of expression of any one or more Table gene products in brain tissue; presence/absence in brain tissue of various Table 1 gene splice variants; 2) assessment of behavioral symptoms associated with memory and learning; and 3) detection of neurodegeneration. Preferably, the screen will include control values (e.g., the level of production of a Table 1 gene product in the test animal in the absence of test compound(s)). Test substances which are considered positive, i.e., likely to be beneficial in the treatment of schizophrenia, will be those which have a substantial effect upon a schizophrenia associated phenomenon (e.g., test agents that are able to normalize erratic or abnormal behavior or that reduce the level of production of a Table 1 gene product to within the normal range).

The present invention also encompasses the use of cell-based assays or cell-lysate assays (e.g., in vitro transcription or translation assays) to screen for compounds or compositions that modulate the expression of any one or more genes disclosed in Table 1. To this end, constructs containing a reporter sequence linked to a regulatory element of a gene disclosed in Table 1 can be used in engineered cells, or in cell lysate extracts, to screen for compounds that modulate the expression of the reporter gene product at the level of transcription. For example, such assays could be used to identify compounds that modulate the expression or activity of transcription factors involved in expression of any one or more of the genes disclosed in Table 1, or to test the activity of triple helix polynucleotides. Alternatively, engineered cells or translation extracts can be used to screen for compounds (including antisense and ribozyme constructs) that modulate the translation of Table 1 gene mRNA transcripts, and therefore, affect expression of these gene products. Thus, regulatory regions such as a promoter are operatively linked to a gene encoding a reporter molecule such as green fluorescent protein (GFP), luciferase and the like, to create a reporter construct which is regulated by appropriate regulatory

sequences for a gene disclosed in Table 1. The gene construct is then transfected into a desired cell such as a neuronal cell. The baseline expression levels of the reporter molecule are then calculated using conventional methods. The cell is then exposed to a test compound and the level of expression of the reporter molecule is determined and compared to the baseline levels. A compound which reduces the amount of reporter expression is a candidate for the treatment of schizophrenia. A second screening procedure may then be instituted to determine whether the compound affects the level of expression of any one or more genes disclosed in Table 1 by measuring the amount of RNA or protein from the native gene(s). Construction of neuronal cells incorporating a reporter gene for determining the effect of compounds on expression is known, e.g., see, Asselbergs et al., Nucleic Acids Res 27:1826-33(1998), incorporated herein by reference.

Antisense compounds, ribozymes, RNAi, RNA aptamers, antibodies and other geneknockout devices or modulators (collectively referred to for convenience as the "modulators") described herein may be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecular structures or mixtures of compounds, as for example, liposomes, receptor targeted molecules, oral, rectal, topical, or other formulations, for assisting in uptake, distribution and/or absorption. Those skilled in the art are familiar with a myriad of techniques to produce such devices.

It is contemplated that the modulators may encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents. The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undue toxicological effects thereto. Such compounds

may be prepared according to conventional methods by one of skill in the art. (Berge et al., "Pharmaceutical Salts," J. of Pharma Sci., 1977, 66, 1-19). The term "prodrug" indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides may be prepared as SATE [(S-acetyl-2-thioethyl)phosphate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin et al., or in WO 94/26764 to Imbach et al.

The modulators herein can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits. For therapeutics, an animal, preferably a human, suspected of having a schizophrenic disease or disorder which can be treated by modulating the expression of one or more genes disclosed in Table 1, is treated by administering modulators in accordance with this invention. The modulators can be utilized in pharmaceutical compositions by adding an effective amount of one or more modulators to a suitable pharmaceutically acceptable diluent or carrier. Those skilled in the art are familiar with numerous techniques and formulations utilized to compound pharmaceutical compositions. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of liquids, powders or aerosols, including by nebulizer; intratracheal, intranasal, enteral, epidermal and transdermal), oral, sublingual, buccal or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; intramedullary or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at least one 2'-O-methoxyethyl modification may be useful for oral administration.

Pharmaceutical compositions for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily

bases, thickeners and the like may be necessary or desirable. Compositions and formulations for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, troches or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable. Compositions for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions that may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients. Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, suspensions, foams and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids, according to conventional methods, by one of skill in the art.

The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product. Further details on techniques for formulation and administration of numerous dosage forms may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, Pa.). The compositions may be administered alone or in combination with at least one other agent, such as stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs or hormones.

Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such

as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

Pharmaceutical compositions suitable for use in the invention include compositions wherein the modulators are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art. For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans. A therapeutically effective dose refers to that amount of active ingredient, which ameliorates, partially or completely, the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED₅₀ (the dose therapeutically effective in 50% of the population) and LD₅₀ (the dose lethal to 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD₅₀/ED₅₀. Pharmaceutical compositions that exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The

dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner in light of factors related to the subject that require treatment. Dosage and administration are adjusted to provide sufficient levels of the modulators to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation. Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g per kilogram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

All references cited herein are incorporated by reference in their entireties. The following examples are included for purposes of illustration and should not be construed as limiting the present invention.

EXAMPLE 1
DNA Microarray Analysis

Human anterior cingulate samples are obtained from 20 normal and 20 schizophrenic deceased subjects (Maryland Psychiatric Research Clinic, Baltimore, Maryland). Good quality RNA was obtained from 19 normal ("N") and 18 schizophrenic ("S") samples.

The microarray analysis is performed essentially as follows. Briefly, 5 μ g or less total RNA is used to synthesize cDNA which is then used as a template to generate biotinylated cRNA. 15 to 30 μ g labeled RNA is obtained and hybridized to Affymetrix (Santa Clara, CA) Human Genome U95Av2 Arrays of the GeneChip® Human Genome U95 Set (HG-U95Av2 contains \approx 12,000 sequences of full length genes) in accordance with the protocols found in the GeneChip® technical manual. Each sample is profiled in duplicate. After sample hybridization, microarrays are washed and scanned with a laser scanner.

The images obtained are used to generate absolute text files for analysis using Affymetrix GeneChip® Gene Expression Analysis Algorithms version 4. Differentially expressed genes between the normal and schizophrenic derived samples are ranked using a pattern recognition algorithm developed in accordance with established principles which generated a score for each gene being compared. The following three conditions are required for a score (equal to the mean fold change) to be generated: (1) t-test p-value<0.5%; (2) average fold-change>1.5; (3) maximum mean AvgDiff (expression levels on an Affymetrix chip)>200. If one or more of the above conditions is not met by a gene in comparison, the score assigned is zero. Results indicate that several genes are found to be differentially expressed in schizophrenic patients when compared to normal (see Table 2 below).

EXAMPLE 2

Real Time Quantitative PCR Confirmation Of Differentially Regulated Genes

Probe pairs for real time quantitative PCR (Q-PCR) are designed for the 56 altered genes identified in Example 1. Affymetrix provides a file of sequences from which the probes on the chip are derived. From this file, the sequences corresponding to these 56 altered genes are obtained, and the probe pairs are prepared. Where a good pair of primers cannot be obtained from Affymetrix

sequence, a longer sequence can be obtained from Ref Seq. (See Pruitt KD, Maglott DR Nucleic Acids Res 2001 Jan 1;29(1):137-140;.Pruitt KD, et al. Trends Genet. 2000 Jan;16(1):44-47) with a good BLAST score against the Affymetrix sequence and the primers are designed from that sequence. The sequences of the probe pairs and the best RefSeq or Genbank hits are presented in Table 2. Most were detected as differentially expressed in schizophrenic patients compared to normal by Affymetrix GeneChips®. ACTB and GAPD were included as controls.

Table 2

Oligopair	PCR Primer Sequences		RefSeq or GenBank IDs	GeneName
SZ1-29	CACCCAGCAGAGCAG TGTGA (Seq ID No 1)	TTTTGCTTTATTTCT GAATGGTCATCT (Seq ID No 59)	NM_003651	Cold shock domain protein A (CSDA)
SZ1-25	GAGTCTGAAGGACCC TAGTTCCCTAGA (Seq ID No 2)	TCTGTCCCTTCACC TCTGATCA (Seq ID No 60)	NM_007021	Decidual protein induced by progesterone (DEPP)
SZ1-11	TCGCCCACAAACTGA TTTCTC (Seq ID No 3)	ACGCATTGCACTT TCCTCTT (Seq ID No 61)	NM_001124	Adrenomedullin (ADM)
JSZ9	GTGCCTGTAGTGACT GACAAGCA (Seq ID No 4)	AGGCCCGGGTCT AGGA (Seq ID No 62)	NM_002673	Plexin B1 (PLXNB1)
JSZ8	TTCTGACAACTGGTG GCAGATT (Seq ID No 5)	TTGGACCCAGACG GGAAA (Seq ID No 63)	NM_002509	NK2 transcription factor homolog B (NKX2B)
JSZ7	GCCTCCCAGTGCAAA TCCT (Seq ID No 6)	CAGGGAGAAGAAC TGGGAGTTAACT (Seq ID No 64)	NM_013279	Chromosome 11 ORF 9 (C11orf9)
JSZ6	GACCTGTTGTAATTG CTCCTCATGT (Seq ID No 7)	ACGGCAAGGTATC GACAGGAT (Seq ID No 65)	AF305057	RTS gene (RTS)
JSZ5A	TATTAACACAGGATAAC CCTTGAATGTAGCA (Seq ID No 8)	CCTCGGCCCTGGT CGTT (Seq ID No 66)	NM_004636	Immunoglobulin domain Ig secreted semaphorin3 (SEMA3B)
JSZ57	ACATGCCGTTGCTCA AAGCT (Seq ID No 9)	GCCATCAACTTCAA TTCCCTTTTC (Seq ID No 67)	NM_000784	Cytochrome P450 subfamily XXVIIA (CYP27A1)
JSZ56B	CAAGCAGAACTGGGT TCAGGAT (Seq ID No 10)	TTAGCTGCAGATT TTGGGTTGT (Seq ID No 68)	NM_002982	Small inducible cytokineA2 (SCYA2)
JSZ55B	GGACTCGATTCTGCC CTTCA (Seq ID No 11)	ACAATGGGCTCGAC TTAGCATAA (Seq ID No 69)	NM_004123	Gastric inhibitory polypeptide (GIP)
JSZ54A	AAGGGATTCGGCCCA ATAAT (Seq ID No 12)	CAGAGACCAAGAA GGTCAAGATGTACT (Seq ID No 70)	NM_001686	ATP synthaseH+transporting mitochondrial F1 complex beta polypeptide(ATP5B)
JSZ53C	TCAATCCTGCATCCC CCATA (Seq ID No 13)	ACAGCCACCAGTGA GCTTCCT (Seq ID No 71)	NM_001511	GRO1 oncogene melanoma growth stimulating activityalpha (GRO1)
JSZ52A	ATGATCCTATTCTGTG TTAGCTCCAAT (Seq ID No 14)	TTCTTAAGGCTGTA ATTTATGCACAGTT (Seq ID No 72)	NM_001249	Ectonucleoside triphosphate diphosphohydrolase 5 (ENTPD5)
JSZ51	GACCCACCAGTGCCT TCTGT (Seq ID No 15)	CTCCCCACTTTGGG CACTTA (Seq ID No 73)	NM_002391	Midkine neurite growth-promoting factor 2 (MDK)
JSZ50	CTGCCTTTCTGCG	GACAGAGAGCCGC	NM_000591	CD14 antigen (CD14)

	AACA (Seq ID No 16)	CATCAGT (Seq ID No 74)		
JSZ49	ACAAGCTCAGAGCCC ACATCA (Seq ID No 17)	ATTCCTAAGGGAGG GTGCTTCT (Seq ID No 75)	NM_015319	Tensin 2 (KIAA1075)
JSZ48	AGGGCACACGCAG ACAT (Seq ID No 18)	CCTGGACAAGTTG AAGGACAGA (Seq ID No 76)	BC036944	EST clone IMAGE:5395238
JSZ46	TGGAGTGTGGATCC TGTGA (Seq ID No 19)	CTCCCACAAGAAATG ATGATGTCA (Seq ID No 77)	NM_001277	Choline kinase (CHK)
JSZ45A	GCCCCGATGTCTACT TTTGTG (Seq ID No 20)	TGAAGTCAGGGACA GTCACCAA (Seq ID No 78)	NM_006230	DNA polymerase delta 2 regulatory subunit (POLD2)
JSZ44	TGTACGAGTCGGCCA AGTTG (Seq ID No 21)	GATTTGCAGGGCG ATGTATC (Seq ID No 79)	NM_015675	Growth arrest and DNA-damage-induciblebeta (GADD45B)
JSZ43A	AGGCTGAGCAAGCAG ATGGA (Seq ID No 22)	CTCACCAACCTGCA AAGTGCTA (Seq ID No 80)	NM_000824	Glycine receptor beta(GLRB)
JSZ42A	AAGGCTATGTTTACG TTTACTCATTGT (Seq ID No 23)	TGAGCTGCCCTCT GTCTCT (Seq ID No 81)	NM_022740	3' end of homeodomain interacting protein kinase 2 (HIPK2)
JSZ41	TGAGGCATCGCAATG TAAGACT (Seq ID No 24)	GGGCAGGGAGTTG AAGAAATT (Seq ID No 82)	NM_001276	Chitinase 3-like 1, cartilage glycoprotein-39 (CHI3L1)
JSZ40A	ACCTCCCCCGCGAGT TC (Seq ID No 25)	GAGGCTCCAGCTTA ACGGTATTT (Seq ID No 83)	NG_000006	Genomic alpha globin region (HBAalpha)
JSZ4	CCTCCGGCGTGTGA A (Seq ID No 26)	CCTCTTGATTCCTCC TTTGCTCTT (Seq ID No 84)	NM_139351	Bridging integrator 1(BIN1)
JSZ36	TCTTTGGCTTCAGAAT TGTTTTAGA (Seq ID No 27)	CAGCAAACCTAACCC CATCTCATT (Seq ID No 85)	NM_000794	Dopamine receptor D1(DRD1)
JSZ35	GCTATAATCCCCCTC AGGGCTAT (Seq ID No 28)	TGGAGGGATTGATCT TGGCCATA (Seq ID No 86)	NM_004960	Fusion derived from t12;16 malignant liposarcoma (FUS)
JSZ34A	GTGAATCTGCACCAA GCATGA (Seq ID No 29)	CTAGTGAGAGGGTA GTCAGTAGCCACTT (Seq ID No 87)	NM_004083	DNA-damage-inducibletranscript 3 (DDIT3)
JSZ33	GAGCCGGACTGGAC ATGGT (Seq ID No 30)	CCTGACAGGATCC GGAAGTCT (Seq ID No 88)	NM_000918	Pro collagen protein disulfide isomerase (P4HB)
JSZ32C	CAATGCCCTTTATT CTCTATTACACA (Seq ID No 31)	GTGGAAGGGCGGG AAGTC (Seq ID No 89)	NM_002309	Leukemia inhibitory factor (LIF)
JSZ31A	CCGAGTGTCTCAGT ATATCAGGAA (Seq ID No 32)	CCATCTTATCACC AGAATGAGGAA (Seq ID No 90)	NM_002964	S100 calcium binding protein A8 (S100A8)
JSZ30	TGCAGGCATGGTCCC TTAA (Seq ID No 33)	AGTCAGTTCATCTG GGCATCCT (Seq ID No 91)	NM_004428	Ephrin-A1 (EFNA1)
JSZ3	CAGCGACCTCCTCA TCCA (Seq ID No 34)	AGCCTCTACTGCCA CCATCTAA (Seq ID No 92)	NM_078467	Cyclin-dependent kinase inhibitor 1A p21/Cip1 (CDKN1A)
JSZ2A	GCAGGATGGACTCTT GCACAT (Seq ID No 35)	CAGCCAACAGTGTA GGTCTTGGT (Seq ID No 93)	NM_003254	Tissue inhibitor of metalloproteinase 1 (TIMP1)
JSZ29	TGAACCTCATCAGTTA AAGGCCAAT (Seq ID No 36)	CCCTTCGCGGGCTT CTT (Seq ID No 94)	NM_004746	Discs large homolog-associated protein 1 (DLGAP1)
JSZ28B	CCTCCGGGAAGTCTT GGAA (Seq ID No 37)	GGCCAAACGCACC GTTC (Seq ID No 95)	NM_000756	Corticotropin releasinghormone (CRH)
JSZ27B	GTGTTTGCCTCAGGC CAACT (Seq ID No 38)	CCAGTCTTATTGAA TGTGGGACTT (Seq ID No 96)	NM_016232	Interleukin 1receptor-like 1 (IL1RL1)
JSZ26	AGAGCCCTCCATCAC CTTCA (Seq ID No 39)	CAGCCCTATTCCAC TGAGTTAGTTT (Seq	AF209502	Calpain (CAPN3)

JSZ25	AGCACAAAGAGCCTCT CTCTGTCTAT (Seq ID No 40)	ID No 97) TGTACACGAACTCC TTGGCATT (Seq ID No 98)	NM_016272	Transducer of ERBB22(TOB2)
JSZ24	CTGGGTGAATGCCCT GAAGAA (Seq ID No 41)	ACTTATGCTCCGA GGTGGTACA (Seq ID No 99)	NM_005393	Plexin B3 (PLXNB3)
JSZ23	GGTACCAGCCTGGGA TACTCCAT (Seq ID No 42)	TTCCGGGCTCAGCA TCAT (Seq ID No 100)	NM_004353	Serine or cysteine proteinase inhibitor clade H (SERPINH1)
JSZ22	CCTCGAAATGGACCC CAACT (Seq ID No 43)	GCAGCCCTGGGCA CACT (Seq ID No 101)	NM_005952	Metallothionein 1X(MT1X)
JSZ21	ACGTATCATGCACCA ACTGTGAA (Seq ID No 44)	TCTGGAACAGTCAT TTCCAGTGT (Seq ID No 102)	XM_030707	KIAA0620 protein (KIAA0620)
JSZ20	AAGAAGAAAGTGACCA AGGAGGAGTT (Seq ID No 45)	AGATGGGTTGTGAA GCAATGAGT (Seq ID No 103)	NM_006501	Myelin-associated oligodendrocyte basic protein (MOBP)
JSZ81	AGAGGAGCGGCAGG AGTATGT(Seq ID No 46)	CITGAAACTGCCA AAATTCCA(Seq ID No 104)	NM_004613	Transglutaminase (TGM2)
JSZ18	CCTTCCTCTCTGCAA TGACCTT (Seq ID No 47)	GAGAACTCCTGGTG GACCCTAGT (Seq ID No 105)	NM_005567	Lectin:galactoside-binding soluble 3-binding protein (LGALS3BP)
JSZ17	GCGCCCATTGATGAG CAT (Seq ID No 48)	CATCCTCCCACAGG CCTT (Seq ID No 106)	NM_138924	Guanidinoacetate N-methyltransferase (GAMT)
JSZ16	ACCCCTGCCTTGTAT TGTCA (Seq ID No 49)	GAGAATAACTTAGA TCCGTGCAATAAT AA (Seq ID No 107)	NM_012323	V-maf musculo aponeurotic fibrosarcoma oncogene homolog F (MAFF)
JSZ15	CCTGCTAAAGAACGCTG ACTAATGCA (Seq ID No 50)	GAGTGGCTTCTCAG GCTGATCT (Seq ID No 108)	NM_032978	Dystro brevin alpha (DTNA)
JSZ14A	AAGCCTCAGCAGTTC TTGGATT (Seq ID No 51)	TCATAATTCTGCATT GCACCTCTT (Seq ID No 109)	NM_003182	Tachykinin precursor 1: substance K and P, neuropeptide 1 and 2, neuropeptide L, neuropeptide alpha, K and gamma (TAC1)
JSZ13A	CCATCAAGACGGAGC TGACA (Seq ID No 52)	CCTTCCTCTGCCA TCTGGATT (Seq ID No 110)	NM_007367	RNA binding protein (RALY)
JSZ12A	TAAGAATGGAGCACT ACATGGGAAA (Seq ID No 53)	GGGACGCTGTGTC TCTCCAA (Seq ID No 111)	NM_000731	Cholecystokinin B receptor (CCKBR)
JSZ11	GTTCAGAGAGATAGG TGAGCTCTACCT (Seq ID No 54)	GGTGAAGGCTTCCT CAATGC (Seq ID No 112)	NM_001085	Serine or cysteine proteinase inhibitor clade A member 3 (SERPINA3)
JSZ10C	TCCTCAACACACCCA AGAACGCT (Seq ID No 55)	GAGAACGGCGGGT TCCA (Seq ID No 113)	NM_006185	Nuclear mitotic apparatus protein 1 (NUMA1)
JSZ1	GGAACTTCTATTAC AATCGCTTAGGA (Seq ID No 56)	CAGAGCGGGTGGG TCAGA (Seq ID No 114)	NM_006494	Ets2 repressor factor (ERF)
GAPDH SD	ATGGGGAAAGGTGAAG GTCG (Seq ID No 57)	TAAAAGCAGCCCTG GTGACC (Seq ID No 115)	NM_002046	Glyceraldehyde-3-phosphate dehydrogenase (GAPD)
Actin2	AAGGATTCTATGTG GGCGA (Seq ID No 58)	TCCATGTCGCCCA GTTGGT (Seq ID No 116)	NM_001101	beta actin (ACTB)

RNA levels are then measured using Q-PCR. Briefly, cDNA is synthesized using random hexamers, diluted in a master mix containing TAQ polymerase, SybrGreen™ (Molecular Probes, Inc., Eugene, Oregon), unlabeled nucleotides, buffer and water. The mixture is aliquotted into TaqMan® plates (Perkin Elmer) and

pairs of oligonucleotides are added to the appropriate wells. Each sample is assayed in at least duplicate wells and every sample is assayed with every oligonucleotide pair where the transcriptase is omitted from the first reaction (noRT controls). The threshold cycle (C_T) is calculated using Perkin Elmer software ABI Prism ® 7700 Sequence Detection System Revision B. The C_T value is defined as the cycle at which a statistically significant increase in fluorescence (from the SybrGreen™) is detected. A lower C_T value is indicative of a higher mRNA concentration.

cDNA is separately prepared from a subset of 16 N (normal) and 16 S (schizophrenic) samples according to conventional methods. Yield is estimated using PicoGreen™ (Molecular Probes, Inc., Eugene, Oregon) assays. All the genes were measured by Q-PCR run on the individual cDNA samples. The individual C_T values for these genes relative to the actin level are examined and t-test and Kruskal Wallace p-values are calculated to test the null hypothesis that the two samples N and S are derived from the same population. Data indicate that thirteen genes are found to be differentially expressed between all the normal and schizophrenic anterior cingulate samples. These genes are listed in Table 3

Table 3

Genes upregulated in all schizophrenics relative to all the normals		
Oligopair	RefSeq or GenBank IDs	GeneName
SZ1-29	NM_003651	Cold shock domain protein A (CSDA)*
SZ1-25	NM_007021	Decidual protein induced by progesterone (DEPP)*
SZ1-11	NM_001124	Adrenomedullin (ADM)*
JSZ56B	NM_002982	Small inducible cytokineA2 (SCYA2)
JSZ44	NM_015675	Growth arrest and DNA-damage-induciblebeta (GADD45B)
JSZ34A	NM_004083	DNA-damage-inducibletranscript 3 (DDIT3)
JSZ31A	NM_002964	S100 calcium binding protein A8 (S100A8)
JSZ3	NM_078467	Cyclin-dependent kinase inhibitor 1A p21/Cip1 (CDKN1A)
JSZ27B	NM_016232	Interleukin 1receptor-like 1 (IL1RL1)
JSZ25	NM_016272	Transducer of ERBB2 (TOB2)
JSZ81	NM_004613	Transglutaminase (TGM2)
JSZ16	NM_012323	V-maf musculo aponeurotic fibrosarcoma oncogene homolog F (MAFF)

JSZ11	NM_001085	Serine or cysteine proteinase inhibitor clade A member 3 (SERPINA3)
-------	-----------	---

*Interestingly, three genes that we identified previously as being associated with schizophrenia (decidual protein induced by progesterone (DEPP), adrenomedullin and cold shock domain protein A (cdsA)) are detected in these experiments, confirming the validity of the data disclosed herein.

Hierarchical clustering of the Q-PCR data showed that of the 16 S samples, seven formed a tight cluster. This indicates that based on expression levels of these 56 measured genes, these seven schizophrenic patients are more similar to one another than to any of the other patients or the normal controls. As such, the seven schizophrenic patients may define a subset of the disease, particularly since when these seven patients were compared to the rest of the other S and N patients, the above set of 13 genes as well as a further 9 genes, were significantly differentially regulated. These additional genes are listed in Table 4

Table 4

Genes upregulated in 7 schizophrenics		
Oligopair	RefSeq or GenBank IDs	GeneName
JSZ53C	NM_001511	GRO1 oncogene melanoma growth stimulating activity alpha (GRO1)
JSZ50	NM_000591	CD14 antigen (CD14)
JSZ49	NM_015319	Tensin 2 (KIAA1075)
JSZ41	NM_001276	Chitinase 3-like 1, cartilage glycoprotein-39 (CHI3L1)
JSZ23	NM_004353	Serine or cysteine proteinase inhibitor clade H (SERPINH1)
JSZ22	NM_005952	Metallothionein 1X(MT1X)
JSZ21	XM_030707	KIAA0620 protein (KIAA0620)
JSZ2A	NM_003254	Tissue inhibitor of metalloproteinase 1 (TIMP1)
JSZ10C	NM_006185	Nuclear mitotic apparatus protein 1 (NUMA1)

cDNA sequences

NM_002982: Small inducible cytokineA2 (SCYA2)

GGAACCGAGAGGGCTGAGACTAACCCAGAAACATCCAATTCTCAAACGTGAGCTCGCACTCTCGC
 CTCCAGCATGAAAGTCTCTGCCGCCCTCTGTGCCCTGCTCATAGCAGCCACCTTCATTCCCC
 AAGGGCTCGCTCAGCCAGATGCAATCAATGCCAGTCACCTGCTGTATAACCTCACCAATAGG
 AAGATCTCAGTGCAGAGGCTCGCGAGCTATAGAAGAATCACCAAGCAGCAAGTGTCCCAGAAG
 CTGTGATCTTCAAGACCATTGTGCCAAGGAGATCTGTGCTGACCCCAAGCAGAAGTGGGTTCA
 GGATTCCATGGACCACCTGGACAAGCAAACCCAAACTCCGAAGACTTGAAACACTCACTCCACAAAC
 CCAAGAATCTGCAGCTAACATTATTTCCCCTAGCTTCCCCAGACACCCCTGTTTTATTATAA
 TGAATTGTTGTTGATGTGAAACATTATGCCCTAACGTAATGTTAATTCTTATTAAAGTTATTGATG
 TTTTAAGTTATCTTCACTGGTACTAGTGTGTTTAGATACAGAGACTTGGGAAATTGCTTTCT
 CTTGAACCACAGTTCTACCCCTGGGATGTTTGAGGGTCTTGCAAGAATCATTAAACAAAGAAT
 TTTTTAACATTCCAATGCATTGCTAAATATTATTGTTGAAATGAATTTGTAACATTACACC
 AAATAAATATATTGTACAAAAAAAAAAAAA Seq. ID No. 117

NM_015675: Growth arrest and DNA-damage-induciblebeta (GADD45B)

CTAGCTCTGTGGGAAGGTTTGGGCTCTGGCTGGGATTTGCAATTCTCCCTGGGGACTGCC
 GTGGAGCCGCATCCACTGTGGATTATAATTGCAACATGACGCTGGAAAGAGCTCGTGGCGTGC
 CAACGCGGCGCAGAAGATGCAAGACGGTGACCGCCGGTGGAGGAGCTTTGGTGGCGCTCA
 GCGCCAGGATCGCCTCACAGTGGGGGTGTACGAGTCGGCCAAGTTGATGAATGTGGACCCAGA
 CAGCGTGGTCTCTGCCTTGGCCATTGACGAGGAGGAGGATGACATGCCCTGCAAATC
 CACTTCACGCTCATCCAGTCCCTCTGCTGTGACAACCGACATCACACATCGTGGGGTGTGGGCAA
 TGCGCGCCTGGCGCAGCTCCCTGGGAGAGCCGGCCAGACCCAGGGCACCCACCGAGGCCGAG
 ACCTCCACTGTCTCCCTTACAGAACCCCTCACACGGACGCCCTGGAAAGAGGACCGCAGGCTTGGT
 GGAGGTGGCCAGCTACTGCGAAGAAAGCCGGGCAACAACCAGTGGGTCCCCATCTCTT
 CAGGAACGCTGAGGCCCTCCAGCAGCAGAACATCTGTTGAGTTGCTGCCAACAAACAAAAATAC
 AATAAAATATTGAACCCCTCCCCCCCAGCACAACCCCCCAGAACAAACCCACGAGGACC
 ATCGGGGGCAGGTGTTGGAGACTGAAGAGAAAGAGAGAGAGAGGAGAAGGGAGTGAGGGCCG
 CTGCCGCTTCCCCATACGGAGGGTCCAGACTGTCCACTCGGGGTGGAGTGAGACTGACTG
 CAAGCCCCACCCCTCTTGAGACTGGAGCTGAGCTGAGCGTCTGCATACGAGAGACTTGGTGAACCTG
 GTTGGTCTTGTCTGCACCCCTGACAAGACCAACTTGGGACTTGGGAGCTGGGCTGAAGTT
 GCTCTGTACCCATGAACTCCCAGTTGCGAATTAAAGAGACAATCTATTGTTACTTGCACCT
 GTTATTGCAACCACTGAGAGCGAGATGGGAGCATAGATATCTATTTTACTATGAGG
 GCCTTGTAAATAATTCTAAAGCCTCAAAAAAA Seq. ID No. 118

NM_002964: S100 calcium binding protein A8 (S100A8)

ATGTCTCTGTCACTGTCTTCAGAAGACCTGGTGGGCAAGTCCGTGGGCATCATGTTGACCG
 AGCTGGAGAAAGCCTGAACTCTATCATCGACGTCTACCACAAGTACTCCCTGATAAAGGGGAAT
 TTCCATGCCGTCTACAGGGATGACCTGAAGAAATTGCTAGAGACCGAGTGTCCCTCAGTATATCAG
 GAAAAAGGGTGCAGACGTCTGGTCAAAGAGTTGGATATCACACTGATGGTGCAGTTACTCC
 AGGAGTTCTCATTCTGGTATAAAGATGGCGTGGCAGCCCACAAAAAAAGCCATGAAGAAAG
 CCACAAAGAGTAGCTGAGTTACTGGGCCAGAGGCTGGGCCCCATGTACCTGCAGAATA
 ATAAAGTCATCAATACCTCAAAAAAAAAAAAAA Seq. ID No. 119

NM_078467: Cyclin-dependent kinase inhibitor 1A p21/Cip1 (CDKN1A)

AGCTGAGGTGTGAGCAGCTGCCGAAGTCAGTTCTGTGGAGCCGGAGCTGGCGCGGATTG
 CCGAGGCACCGAGGCACTCAGAGGGAGGTGAGAGAGAGCGGGCGCAGACAACAGGGGACCCCGGG
 CGGGCGGCCAGAGCCAGCCAGCGTCCCGCGTGTGTCCTGCGTGTCCCGAGGATGCG
 TGTCGCGGGTGTGCTGCGTTACAGGTGTTCTGCGGCAGGCGCCATGTCAAGAACCGGCTG
 GGGATGTCCGTCAAGAACCCATGCGGCAGCAAGGCCTGCCGCCCTTCGGGCCAGTGGACA
 GCGAGCAGCTGAGCCGACTGTGATGCGCTAATGGCGGGCTGCATCCAGGAGGCCGTGAGC

GATGGAACCTCGACTTGTACCGAGACACCACTGGAGGGTACTTCGCCTGGGAGCGTGTGCG
 GGGCCTGGCTGCCAAGCTCTACCTCCCACGGGGCCCCGGCAGGGCGGGATGAGTTGGG
 AGGAGGCAGGCGGCCTGGCACCTCACCTGCTCTGCTCAGGGGACAGCAGAGGAAGACCATGT
 GGACCTGTCAGTGTCTGTACCCCTGTGCCTCGCTCAGGGGAGCAGGCTGAAGGGTCCCCAGGT
 GGACCTGGAGACTCTCAGGGTCAAAACGGCGGCAGACCAGCATGACAGATTCTACCACTCCA
 AACGCCGGCTGATCTCTCCAAGAGGAAGGCCATAATCCGCCACAGGAAGCCTGCAGTCCTGGA
 AGCGCGAGGGCCTCAAAGGCCGCTTACATCTGCCTAGTCTCAGTTGTGTCTTAATT
 ATTATTTGTGTTTAATTAAACACCTCCTCATGTACATACCCCTGGCCGCCCCCTGCCCCCCCAGCC
 TCTGGCATTAGAATTATTAAACAAAAACTAGGCGGTTGAATGAGAGGTTCTAAGAGTGTGGG
 CATTTTATTATGAAATACTATTAAAGCCTCCTCATCCCGTGTCTCCCTTCTCTCTCCCGG
 AGGTTGGGTGGGCCGGCTTACGCCAGCTACTTCCTCCATCGCTGTACAGGCGGTTATGAAATTCA
 CCCTGGAGGGGTGTGGCTCCTCCATCGCTGTACAGGCGGTTATGAAATTCA
 GGACACTCAGACCTGAATTCTTTCATTTGAGAAGTAAACAGATGGCACTTGAAGGGCCTCA
 CCGAGTGGGGCATCATAAAAACTTGGAGTCCCCACCTCCTAAGGTTGGGCAGGGTGA
 CCCTGAAGTGGACAGCAGCTAGGGCTGAGCTGGGACCTGGTACCCCTCTGGCTCTGATA
 CCCTCTGTCTGTGAAGGCAGGGGGAGGGTGGGCTCTGGAGCAGACCACCCCGCCTGCC
 ATGGCCCCCTCTGACCTGCACGGGAGCCCCTCAGTGTGAGCCTTCCCTCTGGCTCC
 CCTGTACCTTTGAGGAGCCCCAGCTACCCCTTCTCCAGCTGGGCTCTGCAATTCCCCCTGC
 TGCTGTCCCTCCCCCTGTCCCTTCCCTCATGTACCTCTCAGCTCCAGGTGGCTCTGAGGTGCC
 TGTCCCACCCCCACCCCCAGCTCAATGGACTGGAAAGGGGAGGGACACACAAGAAGAAGGGCA
 CCCTAGTTCTACCTCAGGCAGCTCAAGCAGCGACCGCCCCCTCCTCTAGCTGTGGGGTAGG
 GTCCCATGTGGTGGCACAGGCCCCCTTGAGTGGGTTATCTCTGTGTTAGGGGATATGATGGG
 GGAGTAGATCTTCTAGGAGGGAGACACTGGCCCTCAATCGTCCAGCGACCTCCTCATCCA
 CCCATCCCTCCCCAGTTCTGACCTTGTGATTAGCAGCGAACAGGAGTCAGACATTAAAGA
 TGGTGGCAGTAGAGGCTATGGACAGGGCATGCCACGTGGCTCATATGGGGCTGGAGTAGTT
 GTCTTCTGGCACTAACGTTGAGCCCCCTGGAGGGCACTGAAGTGCTTAGTGTACTGGAGTAGTT
 GGGTCTGACCCCCAACACCTTCCAGCTCTGTAACATACTGGCCTGGACTGTTCTCTCGGCTC
 CCCATGTGTCTGGTCCCGTTCTCCACCTAGACTGTAAACCTCTCGAGGGCAGGGACCACAC
 CCTGTACTGTTCTGTGTCTTCACAGCTCTCCACAAATGCTGAATATAACAGCAGGTGCTCAATAA
 ATGATTCTTAGTGACTTAAAAAAAAAAAAA Seq. ID No.120

NM_016232: Interleukin 1receptor-like 1 (IL1RL1)

ATGGGGTTTGGATCTTAGCAATTCTCACAAATTCTCATGTATTCCACAGCAGCAAAGTTAGTAAA
 CAATCATGGGCCTGGAAAATGAGGCTTAATTGTAAGATGTCTTAGACAAGGAAAACCTAGTTA
 CACCGTGGATTGGTATTACTCACAAACAAACAAAGTATTCCCACTCAGGAAAGGAAATCGTGTGTT
 TGCCTCAGGCCAACCTCTGAAGTTCTACCAGCTGAAGTTGCTGATTCTGGTATTATACCTGTAT
 TGTAGAAGTCCCACATTCAATAGGACTGGATATGCGAATGTCAACCATAATAAAAACAATCAGA
 TTGCAATGTTCCAGATTATTGATGATTCAACAGTATCTGGATCAGAAAAAAATTCCAAAATT
 TGTCTTACCATGACCTCTACAACCTGGACAGCACCTCTTGAGTGGTTAAGAATTGTCAGGCTCTT
 CAAGGATCAAGGTACAGGGCGCACAAGTCATTGGTGTGATTGATAATGTGATGACTGAGGACGC
 AGGTGATTACACCTGTAATTATACACAATGAAAATGGAGCCAATTATAGTGTGACGGCGACCA
 GGTCTTCAGGTCAAGGATGAGCAAGGGCTTCTGTGTTCCAGTAATCGGAGCCCCCTGCACAA
 AATGAAATAAAGGAAGTGGAAATTGGAAAAAACGCAAACCTAACCTGCTCTGCTTGGAAAA
 GGCAGTCAGTTCTGGCTGCCGTCTGTGGAGCTTAATGGAACAAAATTACAGACTTTGGTGA
 ACCAAGAATTCAACAAGAGGAAGGGCAAATCAAAGTTCAGCAATGGGCTGGCTGTAGACA
 TGGTTTAAAGAATAGCTGACGTGAAGGAAGAGGATTATTGCTGCAGTACGACTGTCTGGCCCTG
 AATTGATGGCTTGAGAAGGCACACCGTAAGACTAAGTAGGAAAAATCCAATTGATCATCATAG
 CATCTACTGCATAATTGCACTATGTAGTGATTGTTAATGCTAATCAATGTCCTGGTTATCATCCTA
 AAAATGTTCTGGATTGAGGCCACTCTGCTCTGGAGAGACATAGCTAACCTTACAAGACTAGGAA
 TGATGGAAAGCTCATGATGCTTATGTTGCTACCCACGGAACTACAAATCCAGTACAGATGGGG
 CCAGTCGTGTAGAGCACTTGTGACCGATTCTGCCTGATGTTCTGAAAATAAATGTGGCTATA
 CCTTATGCAATTATGGGAGAGATATGCTACCTGGAGAAGATGTAGTCAGTCAGTGGAAACCAAC
 ATACGAAAGAGCAGGGCGGCACATTTCATCCTGACCCCTCAGATCACTCACAATAAGGAGTTGC
 CTACGAGCAGGAGGTTGCCCTGCACTGTGCCCTCATCCAGAACGACGCCAGGTGATACTTATT
 GAGATGGAGGCTCTGAGCGAGCTGGACATGCTGCAGGCTGAGGCGCTTCAGGACTCCCTC
 CAGCATCTTATGAAAGTACAGGGGACCATCAAGTGGAGGGAGGACCAATTGCCAATAAAAGGT
 CCCTGAATTCAAATTCTGGAAGCACGTGAGGTACCAAATGCCGTGCAAGCAGCAAATTCCCAGA

AAGGCCTCTAGTTGACTCCCTGGCTGCCAGAAGCAATAG Seq. ID No.121

NM_004613: Transglutaminase 2 (TGM2)

AACAGGCGTACGCCAGTTCTAAACTGAAACAAAACAAAACCTCAAAGTACACCAAAATAGAACCTCCT
 TAAAGCATAAATCTCACGGAGGGTCTGGCCGCAGTGGAAAGGAGCCACCGCCCCCGCCCCGACCATGGC
 CGAGGAGCTGGTCTAGAGAGGTGTGATCTGGAGCTGGAGACCAATGGCGAGACCACACAGGCCGAC
 CTGTGCCGGAGAAGCTGGTGGTGCAGCGGGCCAGCCCTCTGGCTGACCCCTGCACTTTGAGGGCCGCA
 ACTACCAGGCCAGTGTAGACAGTCTCACCTCAGTGTGACCGGCCAGCCCTAGCCAGGAGGCCGG
 GACCAAGGCCGTTTCCACTAACAGAGATGCTGTGGAGGAGGGTACTGGACAGCACCGTGGACCAAG
 CAAGACTGCACCCCTCGCTGCAGCTCACCAACCCGCCAACGCCCATGGCCTGTATGCCCTCAGCC
 TGGAGGCTCCACTGGCTACCAGGGATCCAGCTTGTGCTGGCCACTTCATTTGCTCTAACGCCCTG
 GTGCCAGCGATGCTGTGACCTGGACTCGGAAGAGGAGGGCAGGAGTATGTCTCACCCAGCAGGGC
 TTTATCTACCAAGGGCTCGGCCAGTTCAAGAACATACCTTGAATTGGCAGTTCAAGATGGGA
 TCCTAGACATCTGCTGATCCTCTAGATGTCAACCCCAAGTTCTGAAGAACGCCGGCTGACTGCTC
 CCGCGCAGCAGCCCGTCTACGTGGCCGGTAGTGGCATGGTCAACTGCAACGATGACCAGGGT
 GTGCTGCTGGACGCTGGACACAACACTACGGGACGGCGTCAGCCCATGTCGGATGCCAGCGTGG
 ACATCCTGCCGCGTGGAAAGAACCACGGCTGCCAGCGCTCAAGTATGCCAGTGTGGTCTGCCGC
 CGTGGCCTGCACAGTGTGAGGTGCCTAGGCATCCCTACCCCGTGTGACCAACTACAACCTGGCCAT
 GACCAAGAACAGCAACCTCTCATCGAGTACTCCGCAATGAGTTGGGAGATCCAGGGTACAAGAGCG
 AGATGATCTGGAACCTCCACTGCTGGTGGAGTCGTGGATGACCAGGCCGACCTGCAGCCGGTACGA
 GGGCTGGCAGGCCCTGGACCAACGCCAGGAGAACGGGAAGCTACTGCTGTGGCCAGTTCCA
 GTTCGTGCCATCAAGGAGGGCAGCTGAGCACCAAGTACGATGCCCTTGTCTTGCGGAGGTCAATG
 CCGACGTGGTAGACTGGATCCAGCAGGACGATGGGTCTGTGACAAATCCATCAACCGTCCCTGATCGT
 TGGGCTGAAGATCAGCACTAACAGCGTGGCCAGACGAGCCGGAGGATATACCCACACCTACAAATAC
 CCAGAGGGCTCTAGAGGAGGGAGGCCCTCACAGGGCAACCACTGAACAAACTGCCAGAGGAG
 AGGAGACAGGATGCCATGGGATCCGTGTGGCCAGAGCATGAACATGGCAGTGACTTGACGTCTT
 TGCCACATCACCAACAACACCGCTGAGGAGTACGTCTGCCCTCTGCTCTGTGCCCGCACCGTCAGC
 TACAATGGGATCTGGGGCCCGAGTGTGGCACCAAGTACCTGCTCAACCTAACCTGGAGCCTTCTG
 AGAAGAGCGTCTCTTGATCCTCTATGAGAAATACCGTACTGCCCTACGGAGTCCAACCTCATCAA
 GGTGCGGCCCTCCTCGTGGAGCCAGTTATCAACAGCTACCTGCTGGCTGAGAGGGACCTCACCTGGAG
 AATCCAGAAATCAAGATCCGGATCCTGGGAGGCCAAGCAGAACAGCAAGCTGGCTGAGGGTGTCC
 TGCAAGACCCGCTCCCTGTGGCCCTGGAAAGGCTGCACCTTCACTGTGGAGGGGCCCTGACTGAGGA
 CCAGAAGACGGTGGAGATCCCAGACCCCGTGGAGGGCAGGGAGGAAGTTAAGGTGAGAATGGACCTCGT
 CCGCTCCACATGGGCCCTCCACAAGCTGGTGTGAAACTTCGAGAGCGACAAGCTGAAGGCTGTGAAGGGCT
 TCCGGAATGTCATCATTGGCCCGCTAACGGACCCCTGCTCCCTGCTGAGAGGCCACCTTGAT
 CCCAATCCTTATCCCAAGCTAGTGAGAAATATGCCCTTATTGGGCCCCAGACCCAGGGCAGGGTGG
 GCAGCCTATGGGCCCTCTGGAAATCGAATGTGCCCTTGCCAGATCTCAGGCTGTGGCTCC
 CCACTCACCCCTTGCTGTGAGGAATGCTCTGTGCCAGAAAACAGTGGAGCCCTGACCTGCTGACTG
 GGGCTGGGTGAGAGAGGAAAGACCTACATTCCCTCTGCCAGATGCCCTTGAGAAGGCCACCTTGAT
 ACCCACCATATTGTTGATCTACTCATAGCTCCTGGAGCAGGCAAAAAGGGACAGCATGCCCTTGGC
 TGGATCAGGAATCCAGCTCCCTAGACTGCATCCCGTACCTCTCCATGACTGCACCCAGCTCCAGGGC
 CCTTGGGACACCCAGAGCTGGTGGGACAGTGTAGGCCAACGGTCCCTCACATCCCAGCAGCCAA
 GCTTAATAGCCCTCCCCCTAACCTCACATTGTGAAAGCACCTACTATGTGCTGGGTGCTCCACACTT
 GCTGGGCTCACGGGCCCTCCAACCCATTAAATCACCATGGGAAACTGTTGTGGGCTGCTCCAGGAT
 AAGGAGACTGAGGCTTAGAGAGAGGAGGCCAGCCCCCTCCACACCAAGTGGCCTCGTGGTTATAAGCAAGGC
 TGGGTAATGTAAGGCCAACAGAGCAGAGCTGGGCTCTGACTCTGAGTCCACTGCTCATTATAACCC
 CAGCCTGACCTGAGACTGTGCGAGAGCTGGGCTGTCTGGGCTTTATCAAAAAAAAGACTCAGCCAAGACAAGG
 AGGTAGAGAGGGGACTGGGGACTGGGAGTCAGGCCCTGGCTGGGTTCAAGTCCAGGCTGGCCAGCG
 ACTGCCCTCTCCTCTGGGCCCTTGTTGCTGGTCAGAGGAGTGATTGAACCTGCTCATCTCAA
 GGATCCTCTCCACTCCATGTTGCAATACACAATTCC

Seq ID No 122

NM_012323: V-maf musculo aponeurotic fibrosarcoma oncogene homolog F (MAFF)
 AGTAATTCCGGGAAGCTCGCCTAACACTCCGCGGCCCTGGCCCCCTGCGCCGCCGCCCC

ACAACAAAACCTAGCGCAGCGCTCCCGGGCGCCCGGTTAGAGCGACCTGCGGCTCAGAGCGG
AGGGGAGACTGACCGGAGCGCGGATCGGGACAGCGGCCGGACAGCGCGAGACGCGCGTGT
GTGAGCGCGCCGGACCAAGCGGGCCCAGAAGCGGGTCTGCAGCCCAGAGGGC
ACCTTCTGCAAACATGTCTGTGGATCCCCTATCCAGCAAAGCTCTAAAGATCAAGCGAGAGCTGA
GCGAGAAACACGCCGACCTGTGGACGAGGCGCTGATGGGGCTGTCGGTGCAGCGAGCTGAAC
CGGCATCTGCAGCGGGCTCTCCGCCAGGGTACACGGCTCAAGCAGCGGCCGACACT
CAAAACCGTGGCTACGCCGAGCTGCCGAGGTGAAGCGCGTGTGCCAGAAGGAGGAGCTGCA
GAAGCAGAAGTCGGAGCTGGAGCGAGGTGGACAAGCTGGCGCGAGAACGCCGATGC
GCCTGGAGCTCGACCGCTGCAGCGGAAAGTGCAGGGCGCTGCAGGGCTTCGCGCCTCCGTG
GCCGCCGCCGGCGGGCCCAGCTCGTGGCGCCAGCGTACATCACCATCGTCAAGTC
CACCCCGGGCTCGGGGTCTGGCCCCGCCCAGGGCCGGACCCCGCCACGGCCGGCTCCT
GCTCCTAGTGCCTGCCGCCCGCCATGCCTCAGCCACGCCCTCCGGCCTCAGCTCCCTCCCCAA
AGTGCTGAGCGCCGCTCTGTGCCCAGGTCCCATTCTCTGCAGCACTGGCCCTTGGTGCAC
ACACATTCCCTCGTGGGCCCTGTCTCCTCTGCAGCCCCAAACTGGGACCGAATGACCT
GGGAAGGGGAACCTGGTAGGTTGGGATGGGGAGAGGTCTGGATCTGGGATGCCCTGGC
TGAAAGTTAGCCTTTAGATTGAGAGATACAGAGCGGCTTAGAGAACAGCTGTTGGGGAGA
AGAGGGCACCCCTCATCTGGAAACTGCTCTATTGTGCCAATATGCCCTCCAAACCCCTCCAGG
ATTCAAAGCTAGGTTGGCTGTGACTTACGGGACCGTCTGCAGAAATTGCACTGAAGA
GATGCCCTACCTCTGGTGGGCCCTGGGGTGCCTGGCCTCCGAAACTAAAAGAGTGGTGG
GAAGACTAGTGAACCCAGTCAGGAGGGAAACAGGCCCTGAGGTACATTCACCTAGTGG
TTGTGTTGGACCAAAACCTGGGTGCTCTACTGCTGCCCTGAGTCCAGGCATGGTTTCAGGG
GGACAGTGGACAGGGACTCAGAAATGTGGTGGGAGGGCCTCCCTGGCTTGGAGACCCGCTCTC
TGCAAGGGAGGGGAGAGAAGCAGAGGGAGAGAGAAGGTGACACGGATGGAAGAGTGGGAAG
GAGCTGGCTGGCTCAGCCCTAGGCTGTCCTGCAGCCAGGGTGTCCGGGGCTGGCCAGTC
GAGAAAGGGGCCATGGACTGCTGTGGCAAATAGGGAGACAGAACCCCTGCAGTC
ACTACAGTCTGGAGTGGGTCTAAAGAAGAAGGGTCCCACCTCAACCCCTGTCAGTGTCCACTG
TGGGGTGGGGCTGACCCCTGCCTTGATTGTCATTCTCCTGGAGCCAGTCTCAGTCCCTC
CCCCAACACTGTCCACACTGCCCTCCCCACTGTTATTGACGGATCTAAGTTATTCTCCC
CAGCCAGAGCCGAGCTCCTGCTCCCTGGAAAAGTGGCGTATGCCCTGAGCTGGCTTATA
TTTTATATCTGCAAATAATCACATTATCTTATATTAGGGAAAGCCGGAGAGCAACAAACAAAAA
ATGTTTAAGCCGGCGCGGTGGCTCACATCTGTAATCCCAGCACTTGGGAGTCCAAGGAGGGG
GATCGCTTGAGTCCAGGAGTTGAGACCAGCCTGGACAACATGGTAAACCCCGTCTCACA
AATACAAAAATTAGCCATGCATGGTGGCTATGCCCTGAGTCCCAGCTACTTGGGAGGCTGAGGC
AGGAGGATCACTTAAGCCCAGAAGGCAGAGGGTTGAGTGCAGACTGCACCAACTGCACTCC
AGCCTGGCAACATAGCAAATCTGTCTAAAAAAAAAGTTAAAAAATTGCCCCGCTCTAGA
ATTATTATTCTGACTTACAGCAAGCGAGTTATCGTCTTGTATTGTAGACTTCTAAATAA
AGTCAAATTCTTCTTCCACAGAGAAAAAA Seq. ID No.123

NM_001085: Serine or cysteine proteinase inhibitor clade A member 3 (SERPINA3)

GGAAATCCCTGGAGCAGAGTTGAGAATGGAGAGAATGTTACCTCTGGCTCTGGGGCTTTC
GCGGCTGGGTTCTGCCCTGCTGTCCTCTGCCACCCATAACAGCCCACGGACGAGGAGAATCTGA
CCCAGGAGAACCAAGACCGAGGGACACAGCTGGACCTCGGATTAGCCTCCGCCAACGTGGACT
TCGCTTCAGCCTGTACAAGCAGTTAGTCTGAAGGCCCTGATAAGAATGTCATCTTCTCCCCA
CTGAGCATCTCCACCGCCTGGCCTTCTGTCTCTGGGGGCCATAATACCAACCCGTACAGAGA
TTCTCAAGGCCTCGAGTTACCTCACGGAGACTTACTGAGGCAGAAATTCACTCAGAGCTTCCAG
CACCTCCGCGCACCCCTAACATCAGTCCAGCGATGAGCTGCAGCTGAGTATGGAAATGCCATGT
TTGTCAAAGAGCAACTCAGTCTGGACAGGTTACGGAGGGATGCCAAGAGGGCTGTATGGCTC
CGAGGCCCTTGCACACTGACTTCAGGACTCAGCTCAGCTAAGAACGCTCATCACGACTACGTGA
AGAATGGAACTAGGGGGAAAATCACAGATCTGATCAAGGACCCCGACTCGCAGACAATGATGGT
CCTGGTGAATTACATCTCTTAAAGCCAAATGGGAGATGCCCTTGACCCCCAAGATACTCATCA
GTCAAGGTTCTACTTGAGCAAGAAAAAGTGGTAATGGTGCCATGATGAGTTGCATCACCTGA
CTATACCTTACTCCGGGACGAGGAGCTGCTCTGCACCGTGGTGGAGCTGAAGTACACAGGCAA
TGCCAGCGCACTCTCATCCTCCCTGATCAAGACAAGATGGAGGAAGTGGAAAGCCATGCTGCTC
CCAGAGACCCCTGAAGCGGTGGAGAGACTCTCTGGAGTTAGCTGAGCTACCTGC
CAAAGTTTCCATCTGAGGGACTATAACCTGAACGACATACTCTCCAGCTGGCATTGAGGAA
GCCTTCACCAGCAAGGCTGACCTGTCAGGGATCACAGGGGCCAGGAACCTAGCAGTCTCCAG
GTGGTCCATAAGGTCGTGTCATGTATTGAGGGAGGGCACAGAACGATCTGCTGCCACAGCAG

TCAAAATCACCTCCTTCTGCATTAGTGGAGACAAGGACCATTGTGCGTTAACAGGCCCTTC
 CTGATGATCATTGTCCTACAGACACCCAGAACATCTTCTTCATGAGCAAAGTCACCAATCCCAG
 CAAGCCTAGAGCTTGCATCAAGCAGTGGGCTCTCAGTAAGGAACCTTGAATGCAAGCTGGATG
 CCTGGGTCTCTGGGCACAGCTGGCCCTGTGACCCGTAGTGGCCATGGCATGTGTGGCCCTGT
 CTGCTTATCCTTGAAGGTGACAGCGATTCCCTGTGAAGCTCTCACACGCACAGGGGCCATGG
 ACTCTTCAGTCTGGAGGGCCTGGCCTCCTGACAGCAATAATAATTTCGTTGCC Seq. ID
 No.124

NM_001511: GRO1 oncogene melanoma growth stimulating activity alpha (GRO1)
 CACAGAGCCGGGCCGCAGGCACCTCCTCGCCAGCTTCCGCTCCTCACAGGCCAGAC
 CGCCTGCTGAGCCCCATGGCCCGCTGCTCTCTCCGCCGCCCCCAGCAATCCCCGGCTCCT
 GCGAGTGGCACTGCTCCTGCTCTGGTAGCCGCTGGCCGGCGCAGCAGGAGCGTCCGT
 GCCCACTGAAGTGCCTGCCAGTGCCTGCAGACCCCTGCAGGGAAATTACCCCCAAGAACATCCAA
 AGTGTGAACGTGAAGTCCCCGGACCCCAGTGCCTGCCAAACCGAAGTCATAGCCACACTCAAGA
 ATGGGCGGAAGCTTGCCTCAATCCTGCATCCCCCATAGTTAAGAAAATCATCGAAAAGATGCTG
 AACAGTGACAAATCCAAGTGCACAGAAGGGAGGGAGACAGCTACTGGTGGCTTCTGAAGGA
 GCCCTGCCCCATTAGGAACAGAAGAGGAAGAGAGAGACACAGCTGCAGAGGCCACCTGGATTGT
 GCCTAATGTGTTGAGCATCGCTTAGGAGAAGTCTTCTATTATTATTATTATTAGTTGAAG
 ATTCTATGTTAATATTAGGTGTAAAATAATTAAAGGGTATGATTAACCTACCTGCACACTGTCCT
 ATTATATTCTCTTTGAAATGTCACCCCCAGTTAGTTCAATCTGGATTCTATTTATTAAATTGAAG
 GTAGAATGTTTCAAATGTTCTCCAGTCATTAGTTAATATTCTGAGGAGCCTGCAACATGCCAG
 CCACTGTGATAGAGGCTGGCGGATCCAAGCAAATGCCAATGAGATCATTGTGAAGGCAGGGGA
 ATGTATGTGACATCTGTTGTAACGTGTTAGATGAATGTCAGTTGTTATTATTGAAATGATTTC
 ACAGTGTGTGGTCAACATTCTCATGTTGAAACTTTAAGAAACTAAATGTTCTAAATATCCCTTGA
 CATTATGTCTTCTTGTAAGGCATACTGCCCTGTTAATGGTAGTTTACAGTGTCTGGCTTA
 GAACAAAGGGGCTTAATTATTGATGTTTACAGAGAAATAAAAGCACTTATAG Seq. ID
 No.125

NM_000591: CD14 antigen (CD14)
 CGGGCCGGCCGAAGAGTTACAAGTGTGAAGCCTGAAGCCGGGTGCCGCTGTAGAAAG
 AAGCTAAAGCACTCCAGAGCCTGCTGAGCTCAGAGGTTGGAAGACTTATCGACCATGGAGCG
 CGCGTCCCTGCTTGTGCTGCTGCCGCTGGTGACGCTCTGCGACCCAGCCAGAACCT
 TGTGAGCTGGACGATGAAGATTCCGCTGCGTCTGCAACTTCTCCGAACCTCAGCCGACTGGT
 CGAAGCCTCCAGTGTGCTGCACTAGAGGTGGAGATCATGCCGGCTCAACCTAGA
 GCCGTTCTAAAGCGCGTCGATGCCGACGCCGACCCGCCAGTATGCTGACACGGTCAAGGC
 TCTCCGCGTGCAGGGCTCACAGTGGGAGCCGACAGGTTCTGCTCAGCTACTGGTAGGCC
 CCTCGCTGTGCTAGCGTACTCCGCCTCAAGGAACGTGACGCTGAGGACCTAAAGATAACCGGC
 ACCATGCCCTCGCTGCCCTGGAAGCCACAGGACTTGCACTTCCAGCTGCCCTACGCAACG
 TGCGTGGCGACAGGGCGTTCTGGCTGCCAGCTGCACTGGCTCAAGCCAGGCCTCA
 AGGTACTGAGCATTGCCAACACTCGCCTGCCCTTCTGCGAACAGGTTCGCGCCTTCCC
 GCCCTTACAGCCTAGACCTGTCGACAATCTGGACTGGCGAACGGCGACTGATGGCGGCT
 CTCTGCCCCACAAGTCCGGCCATCCAGAACATCGCGCTGCCAACAGGAATGGAGACGC
 CCACAGCGTGTGCGCCACTGCCGCGGGCAGGTGTGCAAGCCCCACAGCCTAGACCTCAGCC
 ACAACTCGCTGCCGCCACCGTAAACCTAGCGCTCCGAGATGCACTGGTCCAGGCCCTGAA
 CTCCCTCAATCTGCTCGCTGGGCTGGAACAGGTGCCCTAAAGGACTGCCAGCCAAGCTCAGA
 GTGCTCGATCTCAGCTGCAACAGACTGAAACAGGGCGCCGACGCTGACGAGCTGCCGAGGTG
 GATAACCTGACACTGGACGGGAATCCCTTCTGGTCCCTGGAACACTGCCCTCCCCACAGGAGGGCT
 CAATGAACTCCGGCGTGGTCCAGCCTGTCACGTTGACCCCTGTCGGTGGGGGTGCGGGAA
 CCCTGGTGCTGCCAACAGGGGCCGGGGCTTGCCTAACAGATCCAAGACAGAATAATGAATGGAC
 TCAAACCTGCCCTGGCTTCAGGGGAGTCCCGTCAGGACGTTGAGGACTTTGACCAATTCAACCC
 TTTGCCAACCTTATTAAATCTAAC Seq. ID No.126

NM_015319: Tensin 2 (KIAA1075)
 GCACATTCTTCAAGTGACAGCTATAGCCTGCCCAGGGCTGCTGTCCACAGCTGGGGCTGA
 AGACTCCCAGGCCATTAAACCCCTAGCTTCTAGGAAGATTACTCCCCCTTTCAAGGCCCATCC
 ACCTCCCTCCCTGACTCCCAGGACGGGAAGTGGCCATGTTCCAGGAGGGAGGCCGGAGGC

CCATGGATGGGGGTGGAGTATGTGTTGGAGGGGGGACCTCCTGTCAGTCCTCAGGCCCTGG
GACAGCTGCTGAGGAAGGAGAGCAGACCCAGGAGAGCCATGAAGCCTAGGAAAGCTGAGCCTC
ATAGCTTCCGGAGAAGGTTTCCCGAAGAAACCTCCAGTCTGCAAGTATGTAAGGTGACCATC
GATGGGACAGGGCTTCGTCAAGAGTCTGCAAGGTGGCGACGCACAGAAAATGTGAAGCAAAG
GTGACTTCAGCCTGTCAGGCCTTGCCTCCCGTGGAGTTGCGGCAGAACACGGCCCCAGTCAGG
CGCATAGAGCACCTGGGATCCACCAAATCTGAACCACCAAAGCAGCGCAGCACTCTGCCA
GGAGCTTCAGCCTGGACCCGCTATGGAGCGGCCTGGGACTTAGACCTCACACTACGTGACGG
AGCGCATCTTGGCCGCCCTCCCGCGCCGGCGATGAACAGCAGGGCACCGGGCACCTG
CGCAGCTGGCCCAGTGTGCTGCAATCCAAGCACCAGGAGAACAGTACCTGCTCTAACCTTCAG
AGAAAAGGCATGACCTGACCCGCTAAACCCCAAGGTTCAAGACTTGGCTGGCCTGAGCTGCA
TGCTCCACCCCTGGACAAGCTGTGCTCATCTGCAAAGCCATGGAGACATGGCTCAGTGCTGAC
CCACAGCACGTGGTCGTACTATACTGCAAGGGAAACAAGGGCAAGCTGGGTCATCGTTCTG
CCTACATGCACACTACAGCAAGATCTGCAAGGGGCGACCAGGCAGTGGCCACTCTTACCATGCG
GAAATTCTGCGAGGACAAGGTGGCCACAGAACTGCAGCCCTCCAGCGTCGATATATCAGCTAC
TTCAGTGGGCTGCTATCTGGCTCATCAGAATGAACAGCAGCCCTCTTCTGCAGTATGTGCT
CATCCCCATGCTGCCAGCCTTGAACCTGGCACAGGCTTCCAGCCCTTCTTAAATCTACCAAGT
CCATGCAAGCTTGTCTACACATCTGGAGTCTATCACATTGCAAGGCCCTGGTCCCCAGCAGCTTGC
ATCAGCCTGGAGGCCAGCCCTCTCCTCAAAGGCATGTCATGGTAACATGTTACAGGGT
GCCGGGGCAGAGCCAGGGACCCCTCGTGTTCAGTCCAGTCCACACCTGCAACCATCCACGGAC
CACAGCTCACTTCCCCAAGGACCAGCTGACAGGGCTGGACTGATGAGAGGTTCCCCCTCCA
AGCCTCCGTGGAGTTGTCTCTCTCCAGCCCCGAGAAAGATCAAAGGCAGCAGTCCACGGAAC
GACCCCTCGGTCTCTGTGACTACAAACACCAACTGAGGCCAGGGCTGGACTCCTATGAGA
ACTTCAACCAGCACCACGAGGACAGTGTGGATGGCTCTTGACCCACACCCGGGGTCCCCCTGGA
TGGCAGTCCTATGCCAGGTGCAAGCCCTCCGGCAGACCCCCCGGCACCCCTCTCCAGA
GCCCTCACCCCCCATGCTCTGTCAAGCAGCAGTCCAGGCCATTCTCACGCTGACCACA
GAGCCGGCTGCTGAGTCCCTGGCCGGCCGGCCCTACAGCTGCTGAACGGCAGGAGCTGGAT
CGCCTCTAGGAGGCTGCGGAGTGGCCAGTGGGGCCGGAGCTGGCGCGAGACGGCCAT
CCTAGATGACGAAGAGCAGCCCAGTGTGGCGGGAGGCCCCACCTGGAGTGTATCCAGGCCA
TAGGCCTGGCCTCAGCCGCCAGTGTCTCTGCCAGGGCTACCGGGAGGCCCTGCGGGTTCC
CAATGGGGCTACTACCAGGCCAGAGGGAAACCTGGAGAGGAGGAGGAGCTGGCTACGGGGCT
ATGAGGGATCCCCCAGGGCTACGCCAGGGCTGGAGAAGAGGCCCTGCGGATCGCAGTGC
TGTCAAGAGGGCTATACCCCTACCCACCTGAGATGGGGAAACCAGCCACTGGGACTTGGCTA
CCGCGCCCCAGGCTACCGGGAGGTGGTCATCTGGAGGACCCCTGGCTGCCTGCCCTACACCC
ATGCCAGCCTGCGAGGAGAAGCTGGCGCTGCCTACAGCAGCCTGTATGGACTGCCGTGGA
GAGGGAGGCTGGAGAAGGGTGGCAAGTGAAGGCTGGCAAGCCTCTGCACCCAGTGCAGC
CTGGGCACCCGCTGCCTGCTCTGCCTGCCTGTGGCATACCCATGCCCGATGCCCTGACTA
CAGCTGCCAGGCCACCAAGGCAGGGAGGAAGGGCACGAGGGCTGCTCCTACACCATGTG
CCCCGAAGGCAGGTATGGGCATCCAGGGTACCCCTGCCCTGGGACATACAGCTATGGAGGAGC
AGTTCCCAGTTACTGCCAGCATATGGCCGTGTGCCTCATAGCTGTGGCTCTCAGGAGAGGGC
AGAGGGTATCCCAGGCCCTGGTGCCTACCCACGGCTGGCTCCATTCCCCGGAGGCCCG
CCCTATCCACAATCTAGGAAGCTGAGCTACGAGATCCCTACGGAGGAGGGAGGGACAGGTACC
CATTGCCCTGGCACCTGGCTCAGCAGGACCTTGGCATCTGCAGAGTCGCTGGAGGCCGTGTC
CTGGAGGGAGGGCCCCAGTGGGCACAGCAGCAGTGCCTCGGTCTCCCGAGATGCCCATGCA
TGCTCGTCAGAGTTGTCTGGCTCCACGGCCCTGCAACACCAGCAGTCCAGTCCAGGGCAAG
GAAAGCACCCGGCGACAGGACACCAGGTCCCCACCTCAGCGCCACTCAGAGACTGAGTCCT
GGCAGGGCTTGGCCCTGGGAGGGAGGGAGGGAGGGAGGGAGGGAGGGAGGGAGGGAG
AGTGGGCTGAGCCTCTGGCCCTAGGCCAGTCTCTCCGACCTCCCTCCAGCTGCCAGTG
ACTGGCCTCAGGAAAGGAGTCCAGGGGGCACTCAGATGGGCCAGTCCTCGAGGCCCTGTGC
CCACCACACTTCCCTGGCCTCCGCCAGGCCCTGGCAAGGCCCTGAGGGCCCCCGACAGCC
CAGATGGGTCTCCCTCAGTGTGCTTCCCAGATGCCCTGGCTTGTGGCCAGGCCAGGCC
GCCTCAGAGCTACCCAGTGCCTTCCCCCTGGCTGCCTCTATGACACCAATGGCCTAGCC
AGCCCCCAGTCCCTGAGAAACGCCACCTGCCGGGGGGCAACAGCCAGGACCCCTGGGGCC
CAGAGCAGGCATCATGCCAGGCCAGGGCATCAGTCACCATGTCACCTCGCACCTGCTCTC
AGATAATGTCCCCCAAACCCAGAGCCTCTACACAAGAGAGCCAAAGCAATGTCAGTTGTCC
AGGATACATCCAAGTTCTGGTACAAGCCACACCTGTCCTGGTACCAAGCCATTGCCCTGCTGAAG
GACAAGGACCCCTGGGGCCTTCTGATCAGGGACAGTCATTCAAGGAGCTTATGGCTGG
CCCTCAAGGTGGCCACACCGCCACCCAGTGCCAGGCCCTGGAAAGGGAGCCGTGGAACAGC

- 47 -

TGGTCCGCCATTCCTCATCGAGACTGGGCCAAAGGGGTGAAGATCAAGGGCTGCCAGTGA
 GCCCTACTTGGCAGCCTGCGCTTGGCTCCAGCACTCCATCTCCCCATCTCCCTGCCCT
 GCTGCCTGCGCATTCTCAGCAAAGATCCTCTGGAAAGAGACCCCAGAGGCTCCAGTGCCACCAA
 CATGAGCACAGCGGCAGACCTCCTGCGTCAGGGTGCCTGCAGCGTGCTACTTGACCTCA
 GTGGAGACAGAGTCACTGACGGGCCCCAAGCTGTGGCCGGCCAGCTCTGCAGCTTGAGC
 TGTAGCCCCGCCGACACCAGCTGTTGCCACTCAAGGTGTCAAGGCCAGGGCATTACACTGA
 CGGACAACCAAAGGAAGCTTCTTCGCCATTATCCAGTGAACAGCATCACCTCTCCAGC
 ACTGACCTCAAGACGGAGATGGACCAACCCAGACGGGACCACCTCAAGATCTTGTTCG
 TGGCCAAGAAGCCGGAGGCCCTGGAGAATGTGTGACCTCTTGCAAGGCTTGACCCAGA
 TCAGCCTGCTGGGCCATTGTCACCTCATCACCAAAGTTCTACTGGCCAGAGAAAATGAAGGA
 AGGCCACAAGCTCAGAGCCCACATCAACACTGCCCTCCAGCACCCACAGCCCTCACATC
 CCCTGGCCTGGACCCAGGAGACCCAGGAGAAAGCACCCCTCCAGCTGCTAAGTTAAGTGGACAGGCCAC
 CAGGCCTGGACACTGCTCTCCCTGGCCCTGGAGAATGGGAGCTGAGGGGAGGGGATC
 AGATGACCTTGCAATGTGAGCAGATGGCAGAGATGGGTGTGAGGGGAGGGGAGCATCAGCA
 GTTGAGCCCCGAAGGAGATCAGGCAGGCCACCTGCAGGAGAACGTCAGGCCCTCCAGGGGATC
 AGGCCCTGCCAGTCCACCCAGCTGCAGGTGCCAGCACGGCAGGGATGGGAGAGGGGAGGGG
 AGCGAGTCACTGCCTCCTCTGAGCAGAGATTAGGATCACATGAATAGGGAAAAAAGA
 GAGTCTATTTGTCTAATAATAAAAGAATTCTATAAAACTTT Seq. ID No. 127

NM_001276: Chitinase 3-like 1, cartilage glycoprotein-39 (CHI3L1)

AGTGGAGTGGGACAGGTATATAAAGGAAGTACAGGGCCTGGGAAGAGGCCCTGCTAGGTAG
 CTGGCACCAAGGAGCCGTGGCAAGGGAAAGAGGCCACACCCCTGCCCTGCTCTGCTGCAGCCAGA
 ATGGGTGTGAAGGCCTCTCAAACAGGCTTGTGGCTCTGGCTGCTCCAGTGCTGCTGCTGCAT
 ACAAACTGGCTGCTACTACACCAGCTGGCCAGTACCGGGAAAGGGCGATGGGAGCTGCTTCCC
 AGATGCCCTGACCGCTTCTGTACCCACATCATCACAGCTTGCCAATATAAGCAACGATCA
 CATCGACACCTGGGAGTGGAAATGATGTGACGCTCACGGCATGCTCACACACACTCAAGAACAGG
 AACCCCAACCTGAAGACTCTCTTGCTGTGCGAGGATGGAACCTTGGTCTCAAAGATTTCAA
 GATAGCCTCCAACACCCAGAGTCGCCGGACTTCATCAAGTCAGTACCGCCATTGCGCACC
 CATGGCTTGTGGCTGGACCTTGCCTGGCTTACCCCTGGACGGAGAGACAACAGCATT
 CCACCCCTAATCAAGGAATGAAGGCCAATTATAAAGGAAGCCCAGCCAGGGAAAAGCAGCT
 CCTGCTAGCGCAGCACTGTCTGCCGGAAAGGTACCATTGACAGCAGCTATGACATTGCCAAG
 ATATCCCAACACCTGGATTTCATTAGCATCATGACCTACGATTTCATGGAGCCTGGCGTGG
 CACAGGCCATCACAGTCCCTGTTCGAGGTCAGGAGGATGCAAGTCCTGACAGATTGCAAC
 ACTGACTATGCTGGGGTACATGTTGAGGCTGGGGCTCTGCCAGTAAGCTGGTATGGCA
 TCCCCACCTTCGGGAGGGCTTCACTCTGGCTTCTTGAGACTGGTGTGGAGGCCCAATCTCA
 GGACCGGGAAATCCAGGCCGGTTACCAAGGAGGGCAGGGACCCCTGCCACTATGAGATCTGTG
 ACTTCCTCCGCCAGGCCACAGTCATAGAACCCCTGCCAGCAGGTCCCTATGCCACCAAGGG
 CAACCAAGTGGTAGGATACGACGACCAGGAAAGCGTCAAAGCAAGGTGCAGTACCTGAAGGAT
 AGGCAGCTGGCAGGCCATGGTATGGCCCTGGACCTGGATGACTTCAGGGCTCCTCTGC
 GGCCAGGATCTGCGCTTCCCTCACCAATGCCATCAAGGAT
 GCACTCGCTGCAACGTAGCCCTGTTCTGCACACAGCACGGGGCAAGGATGCCCGTCCC
 CCTCTGGCTCCAGCTGGCCGGAGCCTGATCACCTGCCCTGCTGAGTCCCAGGCTGAGCCTCA
 GTCTCCCTCCCTGGGCTATGCAGAGGTCACAACACACAGATTGAGCTCAGCCCTGGTGG
 GCAGAGAGGTAGGGATGGGCTGTGGGGATAGTGAGGCATCGCAATGTAAGACTCGGGATTAG
 TACACACTTGTGATGATTAATGGAAATGTTACAGATCCCCAAGCCTGGCAAGGGAAATTCTTCA
 ACTCCCTGCCCTAGCCCTCTTATCAAAGGACACCATTGGCAAGCTCTACCAAGGAGC
 CAAACATCCTACAAGACACAGTGAACCTAAATTATACCCCTGCCAAAGCCAGCTTGAACCTTC
 ACTTAGGAACGTAATCGTGTCCCTATCCTACTTCCCTTCTAATTCCACAGCTGCTCAATAAG
 TACAAGAGTTAACAGTGTGTTGGCGCTTGTCTTGTCTATCTTGAGCGCCACTAGACCCACT
 GGACTCACCTCCCCATCTTCTGGGCTTCTGAGCCTGGACCCCTGAGCTGCAG
 GATGAAGGCCGCCATGTT Seq. ID No. 128

NM_004353: Serine or cysteine proteinase inhibitor clade H (SERPINH1)

GGTCCTCTGTGGTGACAGCCCACCCCCCAGCCATGCGCTCTCCCTCTGGGCACCTTATGCC
 TCCTGGCTGTGGCCCTGGCAGCCAGGGTAAGAAACCTGTAGAGGCCAGGCCCTGGTACTG
 CGGAGAAGCTGAGTCCAAGGCGACCACACTGGCAGAGCCCAGCACAGGCCCTGGCCTTCAGCC

- 48 -

TGTATCAGGCAATGGCCAAGGACCAGGCAGTGGAGAACATCCTGGTGTACCCGTGGTGGTGG
 CCTCGTCGCTGGGTCTCGTGTGCTGGCGGCAAGGCGACCACGGCGTCGCAGGCCAAGGCA
 GTGCTGAGCGCCGAGCAGCTGCGCGACGAGGAGGTGCACGCCGCTGGGTGAGCTGCTGCG
 CTCACTCAGCAACTCGACGGCGCAACGTGACCTGGAAAGCTGGCAGCCACTGTACGGACC
 CAGCTCAGTGAAGCTCGTGTATGACTTCGTGCGCAGCAGCAAGCAGCACTACAACGTGCGAGCAC
 TCCAAGATCAACTTCCCAGACAAGCGCAGCGCCTGCAGTCCATCAACGAGTGGGCCGCGAG
 ACCACCGACGGCAAGCTGCCGAGGTACCCAAGGACGTGGAGCGCACGGACGGCCCTGCTA
 GTCAACGCCATGTTCTCAAGCCACACTGGGATGAGAAATTCCACCACAAGATGGTGGACAACCG
 TGGCTTCATGGTGAECTCGTCCTATACTGTGGGTGTTACGATGATGCACCGGACAGGCCTCTACA
 ACTACTACGACGACGAGAAGGAGAAGCTGCAGCTGGTGGAGATGCCCTGGCTCACAAGCTCTC
 CAGCCTCATCATCCTCATGCCCATCACGTGGAGCCTCTCGAGCGCCTTGAAAAGCTGCTAACCA
 AAGAGCAGCTGAAGATCTGGATGGGAAGATGCAGAAGAAGGCTGTTGCCATCTCCTGCCAA
 GGGTGTGGTGGAGGTGACCCATGACCTGCAGAAACACCTGGCTGGGCTGACTGAGGC
 CATTGACAAGAACAGGCCGACTTATCACGCATGTCGGCAAGAAGGATCTGACCTGGCCAGT
 GTGTTCCACGCCACGCCCTTGAGTTGGACACAGATGGCAACCCCTTGACCGAGCATCTACG
 GGCGCGAGGAGCTCGCAGCCCCAAGCTGTTCTACGCCGACCCCTTCATTTCTGGTGC
 GGGACACCCAAAGCGGCTCCCTGTATTCTGGGCGCTGGTCCGGCTCAAGGGTGACAAGAT
 GCGAGACGAGTTATAGGGCCTCAGGGTGCACACAGGATGGCAGGAGGCATCCAAAGGCTCTG
 AGACACATGGGTGCTATTGGGGTTGGGGGGAGGTGAGGTACCGAGCCTGGATACTCCATGGAA
 TTCGAGCTCCACTTGGACATGGGCCCCAGATAACCATGATGCTGAGGCCCGAAACTCCACATCCT
 GTGGGACCTGGGCCATAGTCATTGCTGCCCTGAAAGTCCCAGATCAAGCCTGCCTCAATCA
 GTATTCATATTATAGCCAGGTACCTTCTCACCTGTGAGACCAAATTGAGCTCGGGGGTCAGCC
 AGCCCTCTCTGACACTAAACACCTCAGCTGCCCTCCCAGCTATCCAAACCTCTCCCAACTA
 TAAAACTAGGTGCTGCAGCCTGGGACCAGGCACCCCCAGAATGACCTGGCCGAGTGAGGCGA
 TTGAGAAGGAGCTCCAGGAGGGCTTCTGGGAAGACCCCTGGTCAAGAAGCATCGTCTGGCGT
 GTGGGGATGAACTTTGTGTTCTCCCTTTAGTTCTCAAGGAATGGGGGCCAGGGGG
 GGCAATGAGCCTTGTGCTAATCAAATCCGGACTTGTACGTTTCTCACTGAAAC
 CTTTCCAGTGCCAAAAAA Seq. ID No.129

NM_005952: Metallothionein 1X(MT1X)
 ACCACGCTTTCATCTGCCCCGCTCGTGTTTCTCTTGATCGGGAACTCCTGCTTCTCCTGCC
 TCGAAATGGACCCAAGTGCCTCTGCTCGCCTGTTGGCTCCTGTGCGCTGTGCCGGCTCTGCAA
 ATGCAAAGAGTGCACCTGCAAGAAGAGCTGCTGCTCCTGCTGCCCTGTCGGCTGT
 GCCAAGTGTGCCAGGGCTGCATCTGCAAAGGGACGTCAAGACAAGTGCAGCTGCTGTGCC
 Seq. ID No. 130.

XM_030707: KIAA0620 protein (KIAA0620)
 CCCCCCCCCCGCCTCCGCCCTCCGGCTCCGGCTCCGGCTCCGGCCGCGCTCGCCCCATGCA
 CTCGCCGCCGCCGCAGCCCGCGCACGCCCGATGGCTCTCGCGCCGCCGGCGCAGCC
 CTTAGCGCCCGGGCCGCCGCCAGCCCCCGCCGTTCCAGACGCCGCCGCCGGTGCCCGGT
 GCCGCTGCTGTTGCTGCTCCTGGGGGGCGGCCGGGGGCCGGCCCTGGAGATCCAGCGTC
 GGTTCCCTCGCCCACGCCAACAAACTTCGCCCTGGACGGCGCCGGGGACCGTGTAC
 TGGCGGCCGTCAACCGCTCTATCAGCTGCGGGGCCAACCTGAGCCTGGAGGGCGAGGCC
 CGTGGGCCCGGTGCCAGAGCCCGCTGTCACGCTCCCGCAGCTGCCGAGGCCCTCGTGC
 GAGCACCCGCCGCCCTACGGACAACATAACAAGATCCTGCAGCTGGACCCCGGCCAGGGC
 CTGGTAGTCGTGCGGGTCCATCTACCAAGGGCTCTGCCAGCTGCCGGCCGGGGCAACATC
 TCGGCCGTGGCCGTGCGCTTCCGCCGCCGCCGCCAGGCCGCTACGGTGTCC
 CAGCATGCTGAACGTGGCGGCCAACCAACCGAACCGCAGCGTCCACCGTGGGGCTAGTTCTGCC
 CGCCGCCGGCGCGGGGGCAGCCGCTGCTGGCGCACGTACACCGGTTACGGCAGCT
 CCTTCTCCCGCACAACCGCAGCCCTGGAGGGACCAACCGCTTCAGAACACGCCAGATGCCAT
 CCGCTCCCTGGACACGCCGCCGCCACCTGGCCAAGCTCTTCACTTCAACCTCAACCCCTCCGAC
 GACAACATCCTCAAGATCAAGCAGGGCGCCAAGGAGCAGCACAAGCTGGGCTCGTGA
 TTCCTGCACCCGTCGACCCGCCGGGTGCACAGTCCTACCGTACCTGGCGCTAACAGC
 GAGGCAGCGCGCGGGCGACAAGGGAGAGCCAGGCAGGCCGAGCCTGCTGGCGCGCAT
 CCACGGCGCCGGCGGGCGACGCCAAGAAGCTCACCGAGTCTACATCCAGTTGGGCTTGAGTG
 CGCGGGCGGGCGCGGGCGACCTCTACAGCCGCTGGTGTGGTCTTCCAGGCCGG
 AGCGGCTCTTGCTGTCTCGAGCGGCCCCAGGGGCCCCCGCGCTGCTCCGGCCG

CACTCTGCGCCCTCGCTTCCGCGACGTGCGAGCCGCCATCCGAGCTGCGCGCACCGCCTGCT
TCGTGGAACCGGGCGCCGACGTGGTGGCGGTGCTGACAGCGTGGTGCAGGGCACGGGACCG
GCCGCGAGCGCAAGCTAACATCCAGCTCCAGCCAGAGCAGCTGACTGTTGGAGCTGCTCAC
CTGCAGCACCCGCTGTCATCCTGCAGCCCCGAAGGCCACGCCGTGTTCGCGCCCCGGGC
CTCACCTCCGTTGGCCAGCGTCAACAACTACACAGCGGTCTCCTGGCACGGTCAACG
GGAGGCTTCTCAAGATCAACCTGAACGAGAGCATGCAGGGTGGTGAGCAGGCGGTGGTACTG
TGGCCTATGGGGAGCCCGTGCACCATGTCATGCAGTTGACCCAGCAGACTCCGGTTACCTTA
CCTGATGACGTCCCACCAGATGGCCAGGGTGAAGGTCGCCGCTGCAACGTCACCTCACCTG
GGGGACTGCGTGGGTGGCGGGACGCCTACTGCGGCTGGTGTGCCCTGGAGAGACGCGGTGCAC
CTTGCGAGCAGGACTGCACCAATTCCAGCCAGCAGCATTCTGGACCAGTGCAGCGAGGGGGCCC
AGCCGCTGCTCTGCCATGACCGTCCCTGCCAGATCGATGTCGCCCCAGGAGTACCCAGGGCA
TGATCCGAGATCTGGGCAGCCTGCCAGCCTAGTGGCATGGAGATGGCTGTACTATG
GAACAACATCCGCACTGTTGGCTGGGTCCCAGGCCCTGCCCTGGTACCCAGATTGCCACTG
AACCTCTGCGAGGGACCAGTTCCGCCCTCCCCCAACCAGGACACCGTACTGTTGAGA
TGTCTGTGAGGGTCAATGGCGAACATCGTCAAGGCCAATTTCACCATCACGACTGCAGCG
CACTGACAAGTGTACCCCCACACAGCCTGTACCAAGCTGCCCTGCTGGCATGGCCCTGTT
TGGTGCAGCCAGCAGCACTCCTGTGTTCCAACCAGTCTCGGTGCGAGGCCCTACCAAAACCCCA
CGAGCCCTCAGGACTGCCCGGACCCCTGCTCTACCCCTGGCACCCGTGCTTACCGGTGGCT
CCCCAGAACATCTGGTGCCTCTGGCCAACACTGCCTTTCCAGGGTGCAGCCCTGGAGTGTAG
TTTGGGCTGGAGGAGATCTCGAGGCTGTGGGTGAATGAGTCTGTTGACGCTGTGACCAG
GTGGTCTGCACACGACCCGGAAGAGGCCAGGTGTTCCGCTCAGCCTCCAACAAAGGGGGCGG
CCAGCCGATTCTGGACAGCCCTGAGCCATGACAGTCATGGTCTATAACTGTGCCATGGCA
GCCCGACTGTTCCAGTGCCTGGCGGAAGACCTGGTCACCTGTGCGTGTGGAGTGTAG
GCTCCGCGCTGGGGGCTCTGCAGCCATGGCTGGCACCTGCCCGCCCCGAGATCCGC
GCGATTGAGCCCTGAGTGGCCGTTGGACGGTGGGACCTGCTGACCATCCGAGGAAGGAAC
CTGGGCCGGCGGCTCACTGACGTGGCCCACGGCGTGTGGATTGGTGGTGTGGCCTGTGAGCCA
CTGCCTGACAGATAACGGGTGCGGAGGAGTCGTGTGTCACAGGGCAGCCCCAGGACCG
CTCTCAGGTGTGGTGCACGTGAACGCCCTAAGGAGGGCAAGTCCCGGACCGCTTCTCCTACG
TGCTGCCCTGGTCCACTCCCTGGAGCCTACCATGGCCCCAAGGGGGGGCACCAGGATCA
CCATCCATGGGAATGACCTCCATGTAGGCTCCAGCTGGTCTGGTGAACGACACAGACCC
CTGCACGGAGCTGATGCGCACAGATAACAGCATGCCCTGACCATGCCCTGAGGGGGCCCTG
GGCTCCGGTGCCTGTGTGTGCGCTTCCAGCGTCGGGGCTGCGTGCACGGCAACCTCACCT
CTGGTACATGCGAACCCGGTCATCACGCCATCAGTCCCGCCGAGCCCTGTCAGTGGCGG
CAGGACCATCACAGTGGCTGGTGAACGGTGGTCCACATGGTGCAGAATGTGTCCTGGCCTG
CACATTGGCCGGAGCCCACGCTCTGCAAGGTTCTCAACTCCACCCATCACCTGCCGTCCC
CCGGGGCCCTGAGCAACGCATCAGGCCAGTGGACTTCTCATCAATGGCCGGCTACGCAG
ACGAGGTGGCTGGTGAAGGAGCTACTGGACCCAGGGAGGAGGACAGCAGGGCAGCAGGTT
CGCCTGGACTACCTCCCCAACCCACAGTTCTACGGCCAAGAGGGAGAAGTGGATCAAGCACC
ACCCCCGGGAGCCTCTACCCCTGTTATCCACAAGGAGGAGGACAGCCTGGGGCTCCAGAGTC
ACGAGTACCGGGTCAAGATAAGGCCAAGTAAGCTGCGACATCCAGATTGTCCTGACAGAAATCATC
CACTGCTCGGTCAACGAGTCCCTGGCGGGCGTGGGGCAGCTGCCCATCACAAATCCAGGT
GGGAACCTCAACCAGACCATGCCACACTGCAAGCTGGGGGAGCGAGACGCCATCATCGT
TCCATCGTCATCTGCAGCGTCTGCTGCTCTCCGTGGTGGCCCTGTCGTTTTGTACCAA
GAGCCGACGTGCTGAGCGTTACTGGCAGAAAGACGCTGCTGCAAGATGGAGGAGATGGAATCTCA
GATCCGAGAGGAAATCCGAAAGGCTCGCTGAGCTGCAAGACAGACATGACAGATCTGACCAAG
GAGCTGAACCGCAGCCAGGGCATCCCCCTCTGGAGTATAAGCACTCGTACCCGCACCTCT
TCCCCAAGTGTCCCTCCCTTATGAAGAGCGTTACGTGCTGCCCTCCAGACCCCTCAACTCCAG
GGCAGCTCCAGGCACAGGAACCCACCACTGCTGGGAGAGTGGAAAGATTCTGAGAGCTGC
CGGCCAACATGGAAGAGGAAATTAGCTTGTCTCCTCACTACTCAACAAACAAGCACTTCCCTCAT
CGTCTTGTCCACGCGCTGGAGCAGCAGAAGGACTTGCAGGTCAGCGCAGAGGTGCAGCCTGGC
CTCGCTGCTGACCATCGCGCTGCACGGCAAGCTGGAGTACTACACCAGCATCATGAAGGAGCTG
CTGGTGGACCTATTGACGCCCTGGGCCAGAACCCCAAGCTCATGCTGCGCGCACAGAG
TCTGTGGTGGAGAAGATGCTCACCAACTGGATGTCATCTGCATGTACAGCTGTGCGGGAGA
CGGTGGGGAGCCATTCTCCTGCTGCTGTGCCATCAAGCAGCAAACTCAACAAGGGCTCCAT
CGACGCCATCACAGGCAAGGCCGCTACACACTCAGTGAAGGAGTGGCTGCTGCGGGAGAAGCAT
CGAGGCCAAGCCCCGGAACCTGAACGTTGCTCTCCAGGGCTGTCAGGACTCGCTGAGCGT
GCGGGCCATGGACACCGACAGCAGTGAACAGGTCAAGGAGAAGATCCTGGAGGGCCTCTGCAA

- 50 -

GAATGTGCCCTACTCCCAGTGGCCGCGTGCAGAGGACGTCGACCTTGGTGGTCGCCCTCCAGCA
 CACAGAGCTACATCCTTCGGGACCTGGACGACACCTCAGTGGTGGAAAGACGGCCGCAAGAAGCT
 TAACACGCTGGCCCATTACAAGATCCCTGAAGGTGCCTCCCTGGCCATGAGTCTCATAGACAAGA
 AGGACAACACACTGGGCCAGTGAAGAGACTTGGACACAGAGAAGTATTCCATTGGTGCCTGCCT
 ACGGACGGAGCTGGCGGAGGCCAAGAAGTCTCACCGGCAGAGCCATCGCAAGAAGGTGCTCCCG
 GAAATCTACCTGACCCGCTGCTCTCCACCAAGGGCACGTTGCAGAAGTTCTGGATGACCTGTT
 CAAGGCCATTCTGAGTATCCGTGAAGACAAGCCCCACTGGCTGTCAAGTACTTTGACTTCC
 TGGAGGAGCAGGCTGAGAAGAGGGGAATCTCGACCCGACACCCCTACACATCTGGAAAGACCA
 ACAGCCTCCTCTCCGGTTCTGGGTGAACATCCTGAAGAACCCCCAGTTGTCTTGACATCGAC
 AAGACAGACCACATCGACGCCGCCCTCAGTCATCGCGCAGGCCCTCATCGACGCCGCTGCTCCA
 TCTCTGACCTGCAGCTGGCAAGGATTGCCAACCAACAAGCTCCTCTACGCCAACGGAGATTCC
 TGAGTACCGGAAGATCGTGCAGCGCTACTACAAGCAGATCCAGGACATGACGCCGCTCAGCGAG
 CAAGAGATGAATGCCCATCTGGCCGAGGAGTCGAGGAAATACCAAGAATGAGTTAACACCAATG
 TGGCCATGGCAGAGATTATAAGTACGCCAAGAGGTATGCCGCAGATCATGCCGCCGCTGGA
 GGCCAACCCCACGGCCGGAGGACACAACACTGCAGCACAAGTTGAGCAGGTGGCTTGAT
 GGAGGACAACATCTACGAGTGCTACAGTGAGGCTGAGACACATGGAGAGTTGGTCAGGCTGCT
 GCTGGGAGAAATGGACGCCACTGGCCTCAACTTGATCTTCTACCCCGTGCCTGTGACTCAGA
 CTGGGAAATACTGAGCAGAGACGGCTGGGGGGCAGGAGGGCTGCTCTGAGAC
 AGGGGCGCCCCCGCCTGACCCCTGGGACCCCTCCATCCCCTCCACCTGTCCCCAGATCAGTCT
 CTGGGATGGAGGCCAGAGAGCTGGTCAAGGCTCCAGTTGGCCTGCTGCCAACAGGCCGCTGC
 CCACCCACTTGCTCCACAACGTCCAGTTGGCCTGCTGCCAACAGGCCGCTGC
 CAAGCACAAACTGGGGAGAGGGAGGCCAGGCCAGGGGGAGGCTGCAAGGCCAGAAACTTACCTC
 ATCCACACTGGTGCAGGGAGCCCTCTGAACCTGACCTTGTGGTTCTGCTCAACTACCAA
 AATGTTATCTCCACTTCCCCCTCACCGTAGAGGATCTGGCACAGACAGTTCAAGTAGTGTC
 AGATTGGTTGCTTGGCGGCTGTTGGTAGAGTGAGGCTGCCCCGCCATGGGTGCTCTGT
 GGGCTCTCCAGGAAAAGGAGAGGGGTTAAGATGCACCGAGGCTGAGCTGGCTACTTGATCTG
 CTGAAAGTGTCTAAAGATAGCACCACCTTTTTAAAGCTTTATATATTAAAAACGTATCAT
 GCACCAACTGTGAATAGCTGCCGCTGCGCAGAGGACCCGGGGAGGGTCCCGAGAGGCTCCC
 CATGCAACACTGGAATGACTGTTCCAGAGAGCGGGCAGACCTGGCAGAGCGCCCTGGCGCC
 TGAGACTACCACCCACTCCGTTCTGCCAGAAACGACCCCTGTTGGCCATGGCCATGCCG
 CCCTCGCAGCCAACCTAGCCAGTGTGGACTGGCTCAGAGCCCATGGGGCTGGAGGGGG
 AGCTGGACTCTGAATCTCTTATAATAAAAGCCTTACGG
 AC Seq. ID No.131

NM_003254: Tissue inhibitor of metalloproteinase 1 (TIMP1)

AGGGGCCTTAGCGTGCCGCATGCCGAGATCCAGCGCCAGAGAGACACCAGAGAACCCACCA
 TGGCCCCCTTGAGCCCCTGGCTTCTGGCATCCTGTTGCTGTGGCTGATAGCCCCCAGCAG
 GGCCTGCACCTGTGTCCCACCCACCCACAGACGCCCTCTGCAATTCCGACCTCGTCATCAGG
 GCCAAGTTCGTGGGACACCAGAAGTCAACCAGACCACCTTATACCAGCGTTATGAGATCAAGAT
 GACCAAGATGTATAAGGGTCCAAGCCTAGGGATGCCGCTGACATCCGGTTCTGCTACACC
 CCCGCCATGGAGAGTGTCTGCCAGGCTCCACAGGCTCCACCGCAGCGAGGAGTTCTCA
 TTGCTGGAAAATGCAAGGATGGACTCTTGACATCACTACCTGCAGTTCTGCTGGCTCCCTGGAAC
 AGCCTGAGCTTAGCTCAGCGCCGGGGCTTACCAAGACCTACACTGTTGGCTGTGAGGAATGCA
 CAGTGTTCCTGTTATCCATCCCCGCAAAACTGCAGAGTGGCACTCATTGCTTGAGCG
 CAGCTCCTCCAAGGCTCTGAAAAGGGCTTCCAGTCCGTCACCTTGCTGCCCTGCCCTGGGAGC
 CAGGGCTGTGCACCTGGCAGTCCCTGCCGGTCCCAGATAGCCTGAATCTGCCCGAGTGGAAC
 TGAAGCCTGCACAGTGTCCACCCCTGTTCCACTCCCATCTTCTCCGGACAATGAAATAAGAG
 TTACCAACCCAGC Seq. ID No.132

NM_006185: Nuclear mitotic apparatus protein 1 (NUMA1)

GCCCACGAAGAGGTACGATTCCGGAGAATCGCGAGGGCAGAGCGGGAGCGCGCAGCCAGGTGG
 AAACTAATTCTAAGCCAGACTGCTGGAGATCACCCCTGTTAGTGTGTGGAGGCTTCCACCAAGGA
 GTCTGGAGTGCAATGGCACGATCTGGCTCACTGCAACCTCCACCTCCAGGTTCAAGCGATT
 TCCTGCCTCAGCCTCCAAAGTAGCTGGATTACAGGGCATTGGAGTGAUTGACTGTCTGGCATCACC

AAGATGACACTCACGCCACCCGGGGGCTGCACTCCTCTGGGTGAACAGTCTACACGTGG
CTGACCTGTGGAGGCTGTGCTGCAGCTCAGGACTGCAGCATCTCATCAAGATCATTGACAG
AATCCATGGCACTGAAGAGGGACAGCAAATCTTGAAGCAGCCGGTGTCAAGAGAGACTGGACTTT
GTGTGCAGTTCTGCAGAAAAATCGAAAACATCCCTTCCCCAGAATGCCTGGTATCTGCACA
GAAGGTGCTAGAGGGATCAGAGCTGGAACCTGGCGAAGATGACCATGCTGCTTATACCACTCT
ACCATGAGCTCCAAAAGTCCCAGGGACTGGAACAGTTGAATATAAAATTCAAGGCTGAGTTGGC
TGTCATTCTAAATTGTGCTGGACCATGAGGACGGCTAAACCTTAATGAGGACCTAGAGAACT
TCCTACAGAAAGCTCCTGTGCCTTACACTGTTAGCACATCCCTGAAGAGCTCTCCCCACCT
AGCCACCAGGCCAAGAGGGAGATTGCTCCTAGAGCTACAGAAGGTTGCCTCCTTCCAGTG
GGAACAACCTTCTCAGGTTCTCCAGCTTCCATGGGTGATATCCTGCAGACCCCCACAGTTC
CAGATGAGACGGCTGAAGAAGCAGCTTGCTGATGAGAGAAGTAATAGGGATGAGCTGGAGCTGG
AGCTAGCTGAGAACCGCAAGCTCCTCACCGAGAAGGATGCACAGATAGCCATGATGCAGCAGCG
CATTGACCGCCTAGCCCTGCTGAATGAGAACGAGCCAGGCCACTGGAGGCCAAGGAGCT
TGAGGAGCTGCGTGACAAGAATGAGAGCCTTACCATGCGGCTGCATGAAACCCCTGAAGCAGTGC
CAGGACCTGAAGACAGAGAAGAGCCAGATGGATCGCAAAATCAACCAGCTTCCGGAGGAGAATG
GAGACCTTCCTTAAGCTGCGGAGTTGCCAGTCATCTGCAGCAGCTACAGGATGCCCTCAAT
GAGCTGACGGAGGAGCACAGCAAGGCCACTCAGGAGTGGCTAGAGAAGCAGGCCAGCTGGAG
AAGGAGCTCAGCCAGCCCTGCAAGGACAAGAAATGCCCTGAAGAGAGAAGAACGAAATCCTCAGG
GAAAACCTTCACAGCTGGAAGAACACTTGTCCCAGCTGCAGGATAACCCACCCAGGAGAAGGG
CGAGGTGCTGGGTGATGTCTTGCAAGCTGGAAACCTTGAAGCAAGAGGCCAGCCACTTTGCTGCA
AACAAACACACAGCTCCAAGCCAGGGTAGAGATGCTGGAGACTGAGCAGGCCAGCAGGAAGCC
AAGCTGCTTGTGAGCGGGGCCACTTCGAAGAACAGGAAAGGAGCAGCTGTCTAGCCTGATCACTG
ACCTGCAGAGCTCCATCTCAACCTCAGCCAGGCAAGGAAGAGACTGCTGGAGCAGGCCCTCCAGG
CTCATGGGGCCCGGTTGACTGCCCAGGTGGCTCTGACCTCTGAGCTCACACACTCAATGC
CACCATCCAGCAACAGGATCAAGAACACTGGCTGGCCTGAAGCAGCAGGCCAAAGAGAAGCAGGC
CCAGCTAGCACAGAACCCCTCAACAGCAAGAACAGGCCCTCCAGGCCACCAGTGG
GCAGCTAACGAGCTAGCCTGAAGCAGAAGGAGCAGCAGTTGAAGGAGGTAGCGAGAGCAGGA
GGCAACTAGGCAGGACCATGCCAGCAACTGGCCACTGCTGCAGAGGAGCAGAGGCCCTCCTT
AAGGGAGCAGGGATGCGGCTCTCAAGCAGCTGGAGGCACTGGAGAAGGAGAAGGCTGCCAAGCT
GGAGATTCTGCAGCAGCAACTCAGGTGGCTAATGAAGCCGGACAGTGCCCAGACCTCAGTG
ACACAGGCCAGCGGGAGAAGGCAGAGCTGAGCCGGAGGTGGAGGAACCTCAGGCCCTGTGTT
GAGACAGCCGCCAGGAACAGCAGTGGAGGCCAGGGCCAGGTGAGCTAGAGTTGAGCTG
CGGTCTGAGCAGCAAAAGCAACTGAGAAAGAAAGGGTGGCCAGGAGAAGGACAGCTCCAG
GAGCAGCTCCAGGCCCTCAAAGAGCTTGAAGGTACCAAGGGCAGCCTGAAGAGGAGAAG
CGCAGGGCTGCAGATGCCCTGGAAGAGCAGCAGCGTTGATCTGAGCTGAAGGCAGAGACC
CGAACGCTGGTGGAGCAGCATAAGCGGGAAACGAAAGGAGCTGGAAGAAGAGAGGGCTGGCG
CAAGGGCTGGAGGCTCGATTACTGCAGCTGGGAGGCCATCAGGCTGAGACTGAAGTCCT
GCCGGCAGGGAGCTGGCAGAGGCCATGGCTGCCAGCACACAGCTGAGAGTGAGTGTGAGCAGCT
CGTAAAGAAGTAGCTGCCTGGCGTACGGGTATGAGGATGCCAGCAAGAGGAGGCACAGTAT
GGCGCCATGTTCAAGAACAGCTGATGACTTGAAGGAGGAATGTGAGAAGGCCGCCAGGAG
CTGCAGGAGGCAAAGGAGAAGGTGGCAGGCATAGAATCCCACAGCAGCTCCAGATAAGCCGG
CAGCAGAACAAACTAGCTGAGCTCATGCCAACCTGCCAGAGCACTCCAGCAGGTCCAAGAGA
AGGAAGTCAGGGCCAGAACAGCTTGCAGATGACCTCTCCACTCTGCAGGAAAAGATGGCTGCCAC
CAGCAAAGAGGTGGCCGCTTGGAGACCTGGTGCAGGCCAGGGCAGGTGAGCAGCAGGAACAGC
CTCCCGGGAGTTAGTCAGGAGGCCATGGCTGCCAGAGCAGAGCACAGGCCAGTGGCTGGAAGA
GCAACAGGGACGCCAGTTCTGCAGCACACAGGCAGCGCTGCAGGCTATGGAGCGGGAGGCAGA
GCAGATGGCAATGAGCTGGAACGGCTGCGGGCCGCGCTGATGGAGAGGCCAGGGCAGCAGC
AGGAGGAGCGTGGCAGCAGGAAAGGGAGGTGGCGCGCTGACCCAGGAGCAGGGCCGTG
CCAGGCTGACCTTGCCTGGAGAACGGCCAGAGCAGAGCTTGAAGATGCCAGTGCAGAACGC
CCTCAACGAGCAGCGTGTGGAGTTGCTACCCCTGCAAGAGGCAGTGGCTCATGCCCTGACGGAA
AAGGAAGGCAAGGACCAGGAGTTGGCCAAGCTTGTGGCTGGAGGGCAGGCCAGATAAAAGAG
CTGGAGGAACCTCGGCAAACCGTGAAGCAACTGAAGGAACAGCTGGCTAAGAAAGAAAAGGAGC
ACGCATCTGGCTCAGGAGGCCAATCTGAGGCTGCTGGCAGGACAGGCCAACAGGCCCAAGC
TGGAGGCACTGCCAGGGCAGAGGTGAGCAAGCTGGAACAGCAATGCCAGAAGCAGCAGGAGCAG
CTGACAGCCTGGAACAGCAGCCTCGAGGCTGAGCGGGCCTCCGGCTGAGCAGGACAGTGT
CTGGAGACTCTGCAGGGCAGTTAGAGGAGAAGGCCAGGAGCTAGGGCACAGTCAGAGTGCC
TTAGCCTCGGCCAACGGAGTTGGCTGCCCTCCGCACCAAGGTACAAGACCACAGCAAGGCTG

AAGATGAGTGGAAAGGCCAGGTGGCCGGCAAGAGGCTGAGAGGAAAAATGCCTCA
 TCAGCAGCTTGGAGGAGGAGGTGTCATCCTGAATGCCAGGTCTGGAGAAGGAGGGAGA
 GCAAGGAGTTGAAGCGGCTGGTATGGCCAGTCAGAGAAGGCCAGAAGCTGGAGGAGAGCT
 GCGCCTGCTGCAGGCAGAGACAGCCAGCAACAGTGCCAGAGCTGCAGAACGCAGCTGCTCT
 GCGGGAGGAGGTGCAGAGCCTCCGGGAGGGAGGCTGAGAACAGCGGGTGGCTCAGAGAAC
 CTGCGGCAGGAGCTGACCTCACAGGCTGAGCGTGCAGGAGCTGGGCCAAGAATTGAAGGCG
 TGGCAGGAGAAGTTCTTCAGAAAGAGCAGGCCCTCTCCACCCCTGCAGCTCGAGCACACCAGCA
 CACAGGCCCTGGTGAAGTGCAGCTGCCAGCTAACGCACCTCTGCCAGCAGCTGCAGGCCAGAGC
 AGGCCGCTGCCAGAACGCCACCGTGAGGAGCTGGAGCAGAGCAAGCAGGCCCTGGGAGA
 CTGCGGGCAGAGCTGCTCGGGGCCAGCGGGAGCTGGGAGCTGATTCTCTGCAGGCCAGAA
 GGTGGCAGAGCAGGAGCGAACAGCTCAGCAGCTGCCAGAGAAGGCCAGCTATGCAGAGCA
 GCTGAGCATGCTGAAGAACGGCGATGGCCTGCTGGCAGAGGAGAACCGGGGCTGGGTGAGC
 GGGCCAACCTTGGCCGGCAGTTCTGGAAAGTGGAGTTGGACCAGGCCGGAAAAGTATGTCC
 AAGAGTTGGCAGCCGTACGTGCTGATGCTGAGACCGTCTGGCTGAGGTGAGCGAGAACGAC
 AGAGCACTGCCCGGAGCTGGAGGTGATGACTGCCAAGTATGAGGGTGCAGGCAAGGTCAAGGTCC
 TGGAGGAGAGGCAGCGGTTCCAGGAAGAGAGGCAGAAACTCACTGCCAGGTGGAAAGAACTGA
 GTAAGAAACTGGCTGACTCTGACCAAGCCAGCAAGGTGCAGCAGCAGAAAGCTGAAGGCTGTCCA
 GGCTCAGGGAGGGCAGAGGCCAGCAGGAGGCCAGCGCTTCAGGCCAGCTGAATGAACTGCA
 AGCCCAGTTGAGCCAGAACAGCAGCAGAACCAAGAGCTGCGAGCTGAAGCTGAACGGCTGGGAG
 CAGCTCAGAACAGGAAAACAAGAGCTGCGAGGAGGGACCCACTCAGTATCACCAGCAAGCTGCCTGTACAG
 CAGGCTGGCTGAAGACCAAGGAGGCTGAACAGACCTGCCACCTACTGCCAGGTGCGC
 AGCCTGGAGGCACAGGTTGCCATGCAGACCGCAGCTTCAGGCCACCTACTGCCAGGTGCGC
 GCAACTGATGCTTAAAGAGCCGTGAGGCCAGGCTAACGCCAGCTGGACTTGGAGTATTGACA
 GCCTGGATCTGAGCTGCGAGGAGGGACCCACTCAGTATCACCAGCAAGCTGCCTGTACCCA
 GCCAGACGGCACCAGCGTCCCTGAGAACACGCCCTCACCTATCTCCAGCGCCTGCCAAAA
 GGTAGAAATCCCTGGAGAGTCTACTTCACTCCATCCCTGCTGGAGTCAGGCCCTGGAG
 AGCAGCCTGGACTCCCTGGAGACGTCTCCCTGGACTCGGGTCGTAAGACCCGCTCGCTCGTC
 GGCACCCACGCAAGATCATCACCATGACCAAGAAGCTAGATGTGGAAAGAGCCAGACAG
 CGCCAACTCATCGTTACAGCACGCCAGCTGCTCCCTGCTGGCTCCAGGCTAGCCTGCGAGGCCACC
 TCCTCTACTCAGTCTAGCTGCCCTGGTTCTCCGATTATGGCAACTCAGCCCTGCTCAGCTT
 GCCTGGCTACCAGGCCACACTCGCAGTTCTGCTCGTCTCCAGGCCGGGTGTCCAGTGG
 GGCCCTCCAGGAAGAACAGCTTCTACATGGCACTGCCAGGATGAGCCTGAGCAGCTGGAT
 GACTGGAACCGCATTGCAGAGCTGCAGCAGCGCAATCGAGTGTGCCACCATCTGAAGACCT
 GCTATCCCTGGAGTCCAGGCCCTCCCTGAGCCTGGCACCACATCACAGATGAGGAGATGAAAAC
 TGGAGACCCCAAGAGACCCCTGCGCCAGCCAGCATGCAGCCAATCCAGATAGCCGAGGGCAC
 TGGCATACCACCGGAGCGAGCGCAAACGGGTCTCCCTAGAGCCCCACCAGGGCCCTGGAAC
 TCCTGAGTCTAAGAACGCCACCAGCTGTTCCCACGCCCATGACTCCCCGAGACCGACATGAA
 GGGCGCAAACAGAGCACTACTGAGGCCAGAACAGCAGCTCCAGCTCTACTAACACAGGCTG
 ACCGGCGCCAGTCGATGCCCTCAGCATCCTAACACACCCAGAACAGCTAGGGAACAGCCTCT
 GCGCGGGGAGCCTAAAGAACGCCCTGTCACAGGCCAGGCTCCAGGCTCCACACTCGCAGTGGAACCCG
 CCGTTCTCGCGCATTGCCACCACAGCCAGTGCCGCCACTGCTGCCGCCATTGGTGCACC
 CCTCGAGCCAAGGGCAAGGCCAGCAAGCAACTAAAGGGCCAGTACCAAGTGAAGTGGCCCCACCTGTGT
 CCCGATGCTGCCGTACCTGGCTCTCCGCTACTGTCCTCTCAGTGCCTCTCAGCTCCCA
 GGCAACAGTAGCCAAACCCCTAGAGACAGTGTAGCCTGCCAGGCCATTGGCTGCCCTGG
 TCCCTCACTGGGCCCTCTGGAGCTGGCCAGGGGGCCTGGAGCATGGACAGTGTGGCGCT
 CTCCCTACCTTGCCCTCTTTTCTAAAGCAAAGTCACCTCTCCATCACAAACCAAGATTTGAGGCT
 GGTTTGATGGCTGGCTCTGGGCCAGTCTCCTCTAGCCTCTGGATCTAGAAGGGA
 CCATAAGAGGAGTAGGCCCTGGTCTGACCTGGTGGAGCACCTGCCAGAGGATGCTTTCCAGGA
 CTTGAAGTCCAGGACTGGGTCTGACCTGGTGGAGCACCTGCCAGAGGATGCTTTCCAGGA
 CGGATGGGCCCTGTCTCAGGAGTGGGGTTGGGGACAGCCTCAGCAGCAGCTCACACCC
 ACCTCCCCAGACTGCACGGTGGGATTGGAGTGTAGGGAAAGGTTAAAGGCCGGGAA
 TGGATCTTTCTAAATGTTACTTGTAAATAAGTCTATTTT Seq. ID No. 133

NM_004083: DNA-damage-inducible transcript 3 (DDIT3)

GGCACGAGGGAGAGAGAGAGACTTAAGTCTAAGGCACACTGAGCGTATCATGTTAAAGATGAGCGG
 GTGGCAGCGACAGAGCCAAATCAGAGCTGGAACCTGAGGAGAGAGTGTCAAGAAGGAAGTGT

- 53 -

ATCTTCATACATCACCAACCTGAAAGCAGATGTGCTTCCAGACTGATCCAAC TGCAAGAGATG
GCAGCTGAGTCATTGCCTTCTCCTTGGGACACTGTCCAGCTGGAGCTGGAAGCCTGGTATG
AGGACCTGCAAGAGGTCTGTCTTCAGATGAAAATGGGGTACCTATGTTCACCTCCTGGAAAT
GAAGAGGAAGAATCAAAATCTTCACCACTCTGACCCCTGCTCTGGCTGGTACTGAGGA
GGAGCCAGAACCAAGCAGAGGTACAAGCACCTCCCAGAGCCTCACTCTCCAGATTCCAGTCAG
AGCTCCCTGGCTCAGGAGGAAGAGGGAGGAAGACCAAGGGAGAACCGGAAACAGAGT
GGTCATTCCCCAGCCGGCTGAAAGCAGCGCATGAAGGAGAAAGAACAGGAGAACATGAAAGG
AAAGTGGCACAGCTAGCTGAAGAGAATGAACGGCTCAAGCAGGAAATCGAGCGCCTGACCAGG
GAAGTAGAGGCAGCTGCCGAGCTGTGATTGACCGAATGGTGAATCTGCACCAAGCATGAACAA
TTGGGAGCATCAGTCCCCACTTGGGCCACACTACCCACCTTCCCAGAACGTGGCTACTGACTAC
CCTCTCACTAGTCCAATGATGTGACCCCTCAATCCCACATACGCAGGGGGAAAGGCTTGGAGTAG
ACAAAAGGAAAGGTCTCAGCTGTATATAGAGATTGTACATTATTACTGTCCCTATCTATTA
AAGTGACTTCTATGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
Seq. ID No.134

NM_016272: Transducer of ERBB2 (TOB2)

ACTGGGGCCCACAGTCAGACATGAGCCACTGGTGGGACAGAAAATAGGCTCCTGGTTCTGTGA
TCCANAGTTGGTCTTTCTGTCTATCCCTAGCTGTTGGTCACCCACAGCTTCTGCATATTTCT
CACGGTGCCTCTCATTCCCAGAGCCGCCTGGAGGCCAAGGGCTGTACACGTGCCCTGTGCTGAT
TCTCTGCCTAGGAAAGGACCATGCAGCTAGAGATCAAAGTGGCCCTGAACCTCATCTCCTAC
TTGTACAACAAGCTGCCCGGCGCCGGCAGACCTGTTGGGGAGGGAGCTAGAGCGGCTTTG
AAAAAGAAATATGAAGGCCACTGGTACCCCTGAGAACGCACTGAAAGGCTCTGGCTTCCGCTGTGT
TCACATTGGGAGATGGTGGACCCCGTGGAGCTGGCCGCAAGCAGGAGTGGCCTGGCAGT
GGAAGATGTGCGGGCCAATGTGCTGAGGAGCTGAGTGTCTGGATTGATCCCTTGAGGTGTCC
TACCAAGATTGGTGAGAAGGGAGCTGTGAAAGTGCTGTACCTGGATGACAGTGAGGGTTGCGGTG
CCCCAGAGCTGGACAAGGAGATCAAGAGCAGCTTCAACCCCTGACGCCAGGTGTTGCTGCCAT
TGGCAGCCAGGACAGCTCCCTGTCCAACCTCCATGCCATCCTTGCCAGTCACCCAGCCCT
ACCTTCATTCCCCGCTCCGCTCAGCCCACACCTCACCCACGCCCTCGCTGCCACCAAATT
TGGCTCACTAAGATGAAGAAGGGGGCGGGCAGCAAGTGGTGGGGGTGTAGCCAGCAGTG
GGGCGGGTGGCCAGCAGCCACCAACAGCAGCCTCGCATGGCCCGCTACCCACCAACAGCCTGC
TGAAGCACAAGAGCCTCTCTGTCTATGCATTCACTGAACCTCATCAGGCCAACCCGGCCCT
CAGTCCAGCTCTACCCAAATGCCAAGGAGTTCGTGTACAACGGTGGCTACCCAGCCTCT
TCTTGATGCGGCCGATGCCAGGGCAGCGCACCCAGGCCGTTGGAGGCAGTGGGGCTG
GCACCTGCAACAGCAGCAGCTTGACATGGCCAGGTATTGGAGGTGGTGCACAGCCTCTT
CCTGGAGAAGACACCCTTGTGAAAGGCCTCAGCTACAACCTGAACACCAGTCAGTATCCCAGC
CAGCAGTTCCAGCCGTGGTGTGGCCAAGTGCACCATCTACCTGCCGTGGGCCAGGAGCAC
CCAAGACCACAGAAAAGAGAAGGAAAGGCCAAAAAGAGGAAAAGAGGAAAAAGGAAAAAA
Seq. ID No. 135

Amino acid sequences

NM_002982: Small inducible cytokineA2 (SCYA2)

MKVSAALLCLLIAATFIPQGLAQPDAINAPVTCCYNFTNRKISVQRLASYRRITSSKCP
KEAVIFKTIKEICADPKQKWVQDSMDHLDKQTQTPKT Seq. ID No. 136

NM_015675: Growth arrest and DNA-damage-inducible beta (GADD45B)

MTLEELVACDNAAQKMQTVAAVEELLVAAQRQDRLTVGVYESAKLMNVDPDSVVLCLLA
IDEEEDDIALQIHFTLIQSFCDCNDINIVRVSGNARLAQLLGEPAETQGTTEARDLHCL
PFLQNPHTDWKSHGLVEVASYCEESRGNNQWVPYISLQER Seq. ID No.137

NM_002964: S100 calcium binding protein A8 (S100A8)

MLTELEKALNSIIDVYHKYSLIKGNFHAVYRDDLKKLLETECPQYIRKGADVWFKELEDI
NTDGAVNFQEFLILVIKMGVAAHKKSHEESHKE Seq. ID No.138

NM_078467: Cyclin-dependent kinase inhibitor 1A p21/Cip1 (CDKN1A)

MSEPAGDVRQNPCGSKACRRFLGPVDSEQLSRDCDALMAGCIEARERWNFDFVTETPLE
GDFAWERVRGLGLPKLYLPTGPRRGDRDELGGGRRPGTSPALLQGTAEEDHVDSLSCTLV
PRSGEQAEGSPGGPGDSQGRKRRQTSMTDFYHSKRLIFSKRKP Seq. ID No.139

NM_016232: Interleukin 1receptor-like 1 (IL1RL1)

MGFWILAILTILMYSTAAKFSKQSWGLENEALIVRCPRQGKPSYTVDWYYSQTNKSIPTQ
ERNRVFASGQLLKFLPAEVADSGIYTCIVRSPTFNRTGYANVTIYKKQSDCNVPDYLMS
TVSGSEKNSKICYCPTIDLYNWTAPLEWFKNQCALQGSRYRAHKSFLVIDNVMTEDAGDYT
CKFIHNENGANYSVTATRSFTVKDEQGFSLFPVIGAPAQNEIKEVEIGKANLTCACFG
KGTQFLAAVLWQLNGTKITDFGEPRIQQEEGQNQSFNSNGLACDMVLRIADVKEEDLLQ
YDCLALNLHGLRRHTVRLSRKNPIDHHISIYCIACSVFMLINVLVIIKMFWIEATLL
WRDIAKPYKTRNDGKLYDAYVVYPRNYKSSTDGASRVEHFVHQILPDVLENKGYTLCIY
GRDMLPGEDVVTAVETNIRKSRRHIFILTPQITHNKEFAYEQEVALHCALEQNDAKVILI
EMEALSELDMQLQAEALQDSLQHLMKVQGTIKWREDHIANKRSLSNSKFWKHVRYQMPVPSK
IPRKASSLTPLAAQKQ Seq. ID No.140

NM_004613: Transglutaminase 2 (TGM2)

MAEELVLERCDLELETNGRDHTADLCREKLVVRRQPFWLTLHFEGRNYQASVDSLTSVVTGPAPSQEAGTKA
RFPLRDAVEEGDWTATVVDQQDCTLSSLQLOTTAPAPIGLYRLSLEASTGYQGSSFVLGHFILLFNAWC PADAVYL
DSEEEERQEYVLTQQGFIYQGSAKFIKNI PWNFGQFQDGILDICLILLDVNPFLKNAGRDCSRRSSPVYGRVGS
GMVNCNDQGVLLGRWDNNYGDGVSPMSWIGSVDILRRWKNHGCQRVKYQOCWVFAAVACTVLRCLGIPTRVVTN
YNSAHDQNSNLLIEYFRNEFGEIQGDKSEMIWNFHCVESWMTRPDLQPGYEGWQALDPTPQEKGSEGTYCCGPVP
VRAIKEGDLSTKYDAPFVFAEVNADVDWIQQDDGSVHKSINRSLIVGLKISTKSGVRDEREDITHTYKYPEGSS
EEREAFTRANHLNKLAEKEETGMAMRIRVGQSMNMGSDFDVFVFAHITNNNTAEYVCRLLLCA RTVSYNGILGPECG
TKYLLNLTLEPFSEKSVPLCILYEKYRDCLTESNLIKVRALLVEPVINSYLLAERDLYLENPEIKIRILGPEKQK
RKLVAEVSLQNPLPVALEGCTFTVEGAGLTEEQKTVEIPDPVEAGEEVKVRMDLVPVLMGLHKLVNFESDKLKA
VKGFRNVIIGPA Seq ID No. 141

NM_012323: V-maf musculo aponeurotic fibrosarcoma oncogene homolog F (MAFF)

MSVDPLSSKALKIKRELSENTPHLSDEALMGLSVRELNRHLRGLSAEEVTRLKQRRRTLK
NRGYAASCRVKRVCQKEELQKQKSELEREVDKLARENAAMRLELDALRGKCEALQGFARS
VAAARGPATLVAPASVITIVKSTPGSGSGPAHGPDPAHGPASCS Seq. ID No. 142

NM_001085: Serine or cysteine proteinase inhibitor clade A member 3 (SERPINA3)

MERMLPLLALGLLAAGFCPAVLCHPNPLDEENLTQENQDRGTHVDSLGLASANVDFAFSL
YKQLVLKALDKNVIFSPLSISTALAFSLGAHNTTLEILKASSSPHGDLLRQKFTQSFQ

- 55 -

HLRAPSISSSDELQLSMGNAMFVKEQLSLLDRFTEDAKRLYGSEAFATDFQDSAAKKLI
 NDYVKNGTRGKITDLIKDPDSQTMMVLVNYIFFKAKWEMPFDPQDTHQSRFYLSKKWVM
 VPMMSLHHLTIPYFRDEELSCTVVELKYTGNASALFILPQDKMEEVEAMLLPETLKRWR
 DSLEFREIGELYLPKFSISRDYNLNDILLQLGIEEAFTSKADLSGITGARNLAWSQVVHK
 VVSDVFEEGTEASAATAVKITLLSALVETRTIVRFNRPFLMIIVPTDTQNIFFMSKVTNP
 SKPRACIKQWGSQ Seq. ID No.143

NM_001511: GRO1 oncogene melanoma growth stimulating activityalpha (GRO1)
 MARAALSAAPSNPRLRVALLLLLVAAGRRAAGASVATELRCQCLQTLQGIHPKNIQSV
 NVKSPGPHCAQTEVIATLKNGRKACLNPAPIVKIIKMLNSDKSN Seq. ID No.144

NM_000591: CD14 antigen (CD14)
 MERASCLLLLLLPLVHSATTPPEPCLEDDEDFRCVCNFSEPQPDWSEAFQCVSAVEVEIH
 AGGLNLEPFLKRVADADPRQYADTVKALRVRRLTVGAAQVPAQLLVGALRVlaysrlke
 LTLEDLKGTGMPPLPLEATGLALSSLRLRNVSWATGRSWLAELQQWLKPGLKVLsiaqa
 HSPAFCSEQVRAFPALTSLDSDNPGLGERGLMAALCPHKFPAIQNLALRNTGMETPTGV
 CAALAAAGVQPHSDLSHNSLRATVNPSCAPRCMWSSALNSLNLSFAGLEQVPKGLPAKLR
 VLDLSCNRLNRAPQPDELPEVDNLTLGPNFLVPGTALPHEGSMNSGVVPACARSTLSVG
 VSGTLVLLQGARGFA Seq. ID No.145

NM_015319: Tensin 2 (KIAA1075)
 MDGGGVCVGRGDLLSSPQALGQLRKESRPRRAMKPRKAEPHSFREKVFRKKPPVCVCK
 VTIDGTGVSCRVCKVATHRKCEAKVTSACQALPPVELRRNTAPVRRIEHLGSTKSLNHSK
 QRSTLPRSFSLDPLMERRWDLDLYVTERILAAAFPARPDEQRHRGHLRELAHVQLQSKHR
 DKYLLFNLSERKHDLTRLNPKVQDFGWPELHAPPDKLCSICKAMETWLSADPQHVVVLY
 CKGNKGKLGIVIVSAYMHYSKISAGADQALATLTMRKFCEDKVATELQPSQRRYISYFSGL
 LSGSIRMNSSPLFLHYVLPMLPAFEPGTGFQPFKLKIYQSMQLVYTSGVYHIAGPGPQQQ
 CISLEPALLKGDVMTCYHKGGRTDRTLVFRVQFHTCTIHPQLTFPKDQLDEAWTDE
 RFPFQASVEVFVSSSPEKIKGSTPRNDPSVSDYNTTEPAVRWDSDYENFNQHHEDSVGDS
 LTHTRGPLDGSPYAQVQRPPRQTPPAPSPEPPPPPMLVSSDSGHSSLTTEPAAESPGR
 PPPTAAERQELDRLLGGCGVASGGRGAGRETAILDDEEQPTVGGGPHLGVYGPGRGGLSR
 HCSCRQGYREPCGVPNGGYYRPEGTLERRRLAYGGYEGSPQGYAEASMEKRRLCRSLSEG
 LYPYPPEMGKPATGDFGYRAPGYREVVILEDPGLPALYPCPACEEKLAALPTAALYGLRLE
 REAGEGWASEAGKPLLHPVRPGHPLPLLLPACGHHHAPMPDYSCLKPPKAGEEGHEGCSY
 TMCPEGRYGHPGYPAVTVTSYGGAVPSYCPAYGRVPHSCGSPGEGRGYPSPGAHSPRAGS
 ISPGSPPYPQSRKLSYEIPTEEGGDRYPLPGHLASAGPLASAESLEPVSWREGPSGHSTL
 PRSPRDAPCSASSELSGPSTPLHTSSPVQGKESTRRQDTRSPTSAPTQRILSPGEALPPVS
 QAGTGKAPELPGSGPEPLAPSPVSPTFPPSSPSDWPPQERSPGGHSDGASPRSPVPTTL
 GLRHAPWQGPRGPPDSDGSPLTPVPSQMPWLVASPEPPQSSPTAFPLAASYDTNGLSQ
 PPLPEKRHLPGPGQQPGPWPQEQQASSPARGISHHVTFAPLLSDNVPQTPEPPTQESQSNV
 KFVQDTSKFWYKPHLSRDQAIALLKDKDPAFLIRDHSFQGAYGLALKVATPPPSAQPW
 KGDPVEQLVRHFLJETGPKGVKIKGCPSEPYFGSLSALVSQHSISPISLPCCRILSKDP
 LEETPEAPVPTNMSTAADLLRQGAACSVLYLTSVETESTLTGPQAVARASSAALSCSPRPT
 PAVVHFKVSAQGITLTDNQRKLFRRHYPVNSITFSSTDQDRRWTNPDGTTSKIFGFVA
 KKPGSPWENVCHLFAELDPDQPAGAIVTFITKVLLGQRK Seq. ID No. 146

NM_001276: Chitinase 3-like 1, cartilage glycoprotein-39 (CHI3L1)
 MGVKASQTGFVVLVLLQCCSAYKLVYYTSWSQYREGDGSCFPDALDRFLCTHIIYSFAN
 ISNDHIDTWEWNDVTLYGMMLNTLKNRNPNLKTLSSVGGWNFGSQRFSKIASNTQSRRFI
 KSVPPFLRTHGFDGLDLAWLYPGRRDKQHFTTLIKEMKAIFIKEAQPQKKQLLSAA
 GKVTIDSSYDIAKISQHLDFISIMTYDFHGAWRGTTGHHSPLFRGQEDASPDFSNTDYA
 VGYMLRLGAPASKLVMGIPTFGRSFTLASSETVGAPISGPGIPGRFTKEAGTLAYYEIC
 DFLRGATVHRTLGGQQVYATKGNQWVGYDDQESVSKVQYLNDRQLAGAMWALDLDDFQ
 GSFCGQDRLFPLTNAIKDALAAT Seq. ID No.147

NM_004353: Serine or cysteine proteinase inhibitor clade H (SERPINH1)
 MRSLLLGTLCALLAVALAAEVKKPVEAAAPGTAEKLSSKATTI LAEPSTGLAFLSLYQAMAKD
 QAVENILVSPVVVASSLGLVSLGGKATTASQAKAVLSAEQLRDEEVHAGLGEELLRSLSNS
 TARNVTKLGSRLYGPSSVFADDFVRSSKQHYNCEHSKINFDPDKRSALQSINEWAQTT
 DGKLPEVTKDVERTDGALLVNAMFFKPHDEKFHHKMDVNRGFMVTRSYTVGVTMMHRTG
 LYNYYDDEKEKLQLVEMPLAHKLSSLJILMPHHVEPLERLEKLLTKEQLKIQWMGKMQKKA
 VAISLPKGVVEVTHDLQKHLAGLGLTEAIDKNKADLSRMSGKKDLYLASVFHATAFELDT
 DGNPFDQDIYGREELRSPKLFYADHPFIFLVRDTQSGSLLFIGRLVRLKGDKMRDEL Seq. ID No.148

NM_005952: Metallothionein 1X(MT1X)
 MDPNCSCSPVGSCACAGSCKCCKTSCCKSCCSCCPVGCAKCAQGCICKGTSDKCSCCA Seq.
 ID No.149

XM_030707: KIAA0620 protein (KIAA0620)
 MAPRAAGGAPLSARA AAAASPPPFQTTPRCVPVLLLLGAARAGALEIQRPFPSPTPTN
 NFALDGAAGTVYLA VNR LQLSGANLSLEAAAVGPVPSLCHAPQLPQASCEHPRRL
 TDNYNKILQDLPQGQLVVVCGSIYQGFCQLRRRGNISAVAVRFPPAAPPAPVTVFPPSML
 NVAANHPNASTVGLVLPPAAGAGGSRLLVGATYTGYGSSFFPRNRSLEDHRFENTPEIAI
 RSLDTRGDLAKLFTFDLNPSSDDNILKIKQGAKEQHKLGFVSAFLHPSDPPPGAQSYAYLA
 LNSEARAGDKEQS QARSLLARICLPHGAGGDAKKLTESYIQLGLQ CAGGAGRGDLYSRLVS
 VFPARERLFAVFERPQGSPAARAAPAA LCAF RFAD VRAA RARTACFVEPAPDV VAVLD
 SVVQGTGPACERKLNQIQLQPEQLDCGA AHLQHPLSILQPLKATPVFRAPGLTSVAVASVN
 NYTAVFLGT VNGRLLKINLNESMQVVSRRVTVAYGEPVHVMQFD PADSGYLYLMTSHQ
 MARVKVAACNVHSTCGDCVGAADAYCGWCALETRCTLQQDCTNSSQQHFWTSASEGPSRC
 PAMTVPSEIDVRQEYPGMILQISGSLPSLSGMEMACDYGNNIRT VARVPGPAFGHQIAY
 CNLLPRDQFPPFPPNQDHVT VEMSVRVNGRNIVKANFTIYDCSRTAQVYPTACTSCLSA
 QWPCFWCSQQHSCVSNQSRCEASPNPTSPQDCPRTL SPLAPVPTGGSQNILVPLANTAF
 FQGAALECSFGLEEIFEAVWVNESVVRC DQV LHTTRKSQVFPPLS LQLKGRPARFLDSPE
 PMTVMVYNCAMGSPDCSQCLGREDLGHLCWVSDGCR LRGPLQPMAGTCPAPEIRAI EPLS
 GPLDGGTLLTIRGRNLGRR LSDVAHGVWIGVACEPLPDRTVSEEIVCTGPAPGPLSG
 VVTVNASKEGKSRDRFSYVLPVHSLEPTMGPKAGGTRITIHGN DLHVGSELQVLVNDTD
 PCTELMRTDTSIACTMPEGALPAPVPCVRFERRGCVHGNLTWYMQNPVITAISPRRSP
 VSGGRTITVAGERFHMVQNVSMAVHHIGREPLC KVLNSTLITCPSPGALS N ASAPVDFF
 INGRAYADEVAVA EELDPEEAQRGSRFRLDYLPNPQFSTAKREKWI KHPGEPLTLVIH
 KEQDSLGLQSHEYRVKIGQVSCDIQIVSDRIIHC SVNESLGA AVGQLPITI QVGNFNQTI
 ATLQLGGSETAIIVSIVICSVL LLSVVALFVFC TKS RRA ERYWQKTLQMEEMESQIRE
 EIRKGFAELQTDMDLT KELNRSQGIPFLEYKHFVTRTFPKCSSL YEE RYVLP SQTLNS
 QGSSQAQETHPLLGEW KIP ESCR PNMEEGISL FSSLLNNKHFLIVFV HALEQQKDFAVRD
 RCSLASL LTIALHGKLEYYT SIMKELLVDLIDASA AKNP KLM RRTESV V EKML TNWMSI
 CMYSCL RETVGE PFF LLLCAIKQQINKGSIDAITGKARY TLSE WLLRENIEAKPRNLNV
 SFQGCGMDSLSVRAMDTDTLTVK EKILEAFCKN VPYSQW PRAEDV D LGGSPPAH RATS F
 GTWTTPQWWKTAARSLTRWPITRSLKVPPWP Seq. ID No.150

NM_003254: Tissue inhibitor of metalloproteinase 1 (TIMP1)
 MAPFEPLASGILLLWLIAPSRACTCVPPHPQTAFCNSDLVIRAKFVGTPEVNQTTLYQR
 YEIKMTKMYKGFQALGDAADIRFVYTPAMESVCGYFHRSHNRSEEFIAGKLQDGLLHIT
 TCSFVAPWNSLSLAQR RGFTKTYVGCEECTVFPCLSIPCKLQSGTHCLWTDQLLQGSEK
 GFQSRHLACLPREPGLCTWQSLRSQIA Seq. ID No.151

NM_006185: Nuclear mitotic apparatus protein 1 (NUMA1)
 MTLHATRGAALLSWVNSLHVADPVEAVLQLQDCSIFIKIIDRIHGT EEGQQILKQPVSER
 LDFVCSFLQKNRKHPSSPECLVSAQKVLEGSELEAKMTMLLYHSTMSSKSPRDWEQFE
 YKIQAE LAVILKFVLDHEDGLNLNEDLENFLQKAPVPSTCSSTFPEELSPPSHQAKREIR
 FLELQKVASSSSGNNF LSGSPASPMGDILQTPQFQMRR LKKQLADERSNRDELELEAEN
 RKLLTEKDAQIAMM QQRIDRLALLNEKQAASPLEPKELEELRDKNESLT MRLHETLKQCQ
 DLKTEKSQMDR KINQLSEENG DLSFKLREFASHLQQLQDALN EEEHSKATQEWLEKQA

QLEKELSAALQDKKCLEEKNEILQGKLSQLEEHLSQLQDNPPQEKGEVLDVLQLETLKQ
 EAATLAANNTQLQARVEMLETERGQQEAKLLAERGHFEEEKQQLSSLTDLQSSISNLSQ
 AKEELEQASQAHGARLTAQVASLTSELTTLNATIQQQDQELAGLKQQAKEQAAQLAQTLQ
 QQEQASQGLRHQVEQLSSSLKQKEQQQLKEVAEKQEATRQDHAQQLATAAEEREASLRERD
 AALKQLEALEKEAAKLEILQQQLQVANEARDSAQTSVTQAQREKAELSRKVEELQACVE
 TARQEQQHEAQAAQVAELELQLRSEQQKATEKERVQAQEKDQLQEQQLQALKESLKVTKGSLEE
 EKRRAADALEEQQRCISELKAETRSLVEQHKRERKELEEEAGRKGLEARLLQLGEAHQA
 ETEVLRRELAEAMAQHTAESECEQLVKVEVAWRDGYEDSQQEEAQYQAMFQEQLMTLKE
 ECEKARQELQEAKEVAGIESHSELQISRQQNKLAELHANLARALQQVQEKEVRAQKLAD
 DLSTLQEKMATSKEVARLETVRKAGEQQETASRELVKEPARAGDRQPWEWLEEQQGRQF
 CSTQAALQAMEREAEQMGNELERLRAALMESQGQQQEERGQQEREVARLTQERGRAQADL
 ALEKAARAEELEMRLQNALNEQRVEFATLQEAHALTEKEGKDQELAKLRGLEAAQIKEL
 EELRQTVKQLKEQLAKKEKEHASGSGAQSEAAGRTEPTGPKLEALRAEVSKLEQQCQKQQ
 EQADSLERSLEAERASRAERDSALETLQGQLEEKAQELGHQSALASAQRELAFFRTKVQ
 DHSKADEDEWKAQVARGRQEAERKNSLISSLEEVSIILNRQVLEKEGESKELKRLVMAESE
 KSQKLEESCACCRQRQPATVPELQNAALLCGRRCRASGREAEKQRVASENLRQE LTSQAE
 RAEELGQELKAWQEKFQKEQALSTLQLEHTSTQALVSELLPAKHLCCQQLQAEQAAAER
 HREELEQSKQAAGGLRAELLRAQRELGEIPLRQKVAEQERTAQQLRAEKASYAEQLSML
 KKAHGLLAEEENRGLGERANLGRQFLEVLDQAREKYVQELAARADAETRLAEVQREAQS
 TARELEVMTAKYEGAKVKVLEERQRFQERQKLTAQVEELSKKLADSDQASKVQQQKLKA
 VQAQGGESQQEAQRFQALQNELQAQLSQKEQAAEHYKLQMEKAKTHYDAKKQQNQELQEQ
 LRSLEQLQKENKELRAEAERLGHELQQAGLKTKEAEQTCRHTAQVRSLEAQVAHADQQL
 RDLGKFQVATDALSKREPQAKPQLDLSIDSLLSCEEGTPLSITSKLPRTQPDGTSVPGE
 PASPISQRLPPKVESLESLYFTPIPARSQAPLESSLDSLGDVFLDSGRKTRSARRRTTI
 INITMTKLDVEEPDSANSSFYSTRSAPASQASLRATSSTQSLARLGSPDYGNNSALLSLP
 GYRPTTRSSARRSQAGVSSGAPPGRNSFYMGTCQDEPEQLDDWNRIAELQQRNRVCPPHL
 KTCYPLESRPSLGLTITDEEMKTGDPQETLRRASMQPIQIAEGTGITRQQRKRVSL
 HQGPGTPESKKATSCFPRPMTPRDRHEGRKQSTTEAQKKAAPASTKQADRRQSMAFSILN
 TPKKLGNSSLRRGASKKALSKASPNTRSGTRRSPRIATTASAATAAIGATPRAKGKAK
 H Seq. ID No.152

NM_004083: DNA-damage-inducible transcript 3 (DDIT3)
 MAAESLPFSFGTLSSWELEAWYEDLQEVLSSDENGGTYVSPPGNEEEEESKIFTTLDPASL
 AWLTEEEPEPAEVTSQSPhSPDSSQSSLAQEEEEEDQGRTRKRKQSGHSPARAGKQRM
 KEKEQENERKVAQLAEEENERLKQEIERLTREVEATRRALIDRMVNLLHQA Seq. ID No.153

NM_016272 Transducer of ERBB2 (TOB2)
 MQLEIKVALNFIISYLYNKLPRRRADLFGEELERLLKKYEGHWYPEKPLKGSGFRCVHI
 GEMVDPVVELAAKRSGLAVEDVRANVPEELSVIDPFEVSYQIGEKGAVKVLYLDDSEGC
 GAPELDKEIKSSFNPDQAQVFVPIGSQDSSLNSPSPSFQGQSPSPTFIPRSAQPIFTTAS
 FAATKFGSTKMKGGGAASGGGVASSGAGGQQPPQPRMARSPTNSLLHKSLSLSMHSL
 NFITANPAPQSQLSPNAKEFVYNGGSPSLFFDAADGQQGSGTPGPFGGSGAGTCNSSFD
 MAQVFGGGANSLFLEKTPFVEGLSYNLNTMQYPSQQFQPVVLAN Seq. ID No.154

The foregoing description illustrates preferred embodiments of the present invention. It should be understood that those skilled in the art will envision modifications of the embodiments that are covered by the following claims.

WHAT IS CLAIMED IS:

1. A method of screening for schizophrenia in a population comprising determining the magnitude of expression, in members of the population, of at least one gene selected from the group consisting of those disclosed in Table 1 in a sample and comparing the magnitude of expression to a baseline magnitude of expression of the gene, wherein increased gene expression indicates the presence of schizophrenia.
2. A method of screening for schizophrenia in a population according to claim 1 wherein the sample is taken from brain, spinal cord, lymphatic fluid, blood, urine or feces.
3. A method of screening for schizophrenia in a population according to claim 2 wherein the sample is taken from the anterior cingulate.
4. A method of screening for schizophrenia in a population according to claim 1 wherein the population is human.
5. A method for diagnosing schizophrenia in a host comprising determining the magnitude of expression of at least one gene selected from the group consisting of those disclosed in Table 1 in a sample and comparing the magnitude of expression to a baseline magnitude of expression of the gene, wherein increased gene expression indicates the presence of schizophrenia.
6. A method for diagnosing schizophrenia in a host according to claim 5 wherein the sample is taken from brain, spinal cord, lymphatic fluid, blood, urine or feces.
7. A method for diagnosing schizophrenia in a host according to claim 6 wherein the sample is taken from the anterior cingulate.

8. A method for diagnosing schizophrenia in a host according to claim 5 wherein the host is human.

9. A method for treating schizophrenia in a host comprising lowering expression of at least one gene selected from the group consisting of those disclosed in Table 1 by administering to the host an expression lowering amount of antisense oligonucleotide.

10. A method for treating schizophrenia in a host according to claim 9 wherein the host is human.

11. A method for treating schizophrenia in a host comprising lowering expression of at least one gene selected from the group consisting of those disclosed in Table 1 by administering to the host an expression lowering amount of a ribozyme which cleaves RNA associated with expression of the gene.

12. A method for treating schizophrenia in a host according to claim 11 wherein the host is human.

13. A method for treating schizophrenia in a host comprising lowering expression of a gene selected from the group consisting of those disclosed in Table 1 by administering one or more nucleic acid molecules designed to promote triple helix formation with said gene .

14. A method for treating schizophrenia in a host according to claim 13 wherein the host is human.

15. A method for treating schizophrenia in a host comprising reducing the amount of at least one protein selected from the group consisting of those encoded by the genes disclosed in Table 1 in a patient by administering an effective amount of antibody or functional antibody fragment sufficient to interfere with the normal activity of the protein.

16. A method for treating schizophrenia in a host according to claim 15 wherein the host is human.

17. A method for treating schizophrenia in a host according to claim 15 wherein the antibody or functional antibody fragment is selected from the group consisting of whole antibody, humanized antibody, chimeric antibody, Fab fragment, Fab' fragment, F(ab')₂ fragment, single chain Fv fragment and diabody.

18. A transgenic nonhuman animal comprising stably integrated in its genome an increased copy number of a gene selected from the group consisting of the genes disclosed in Table 1) wherein said gene is expressed at higher than baseline levels and the animal exhibits schizophrenic behavior.

19. A transgenic nonhuman animal according to claim 18 wherein the transgenic nonhuman animal is a mammal.

20. A transgenic nonhuman animal comprising stably integrated in its genome a gene selected from the group consisting of those disclosed in Table 1 , wherein expression of the gene is enhanced by one or more alterations in regulatory sequences of the gene such that the gene is expressed at higher than baseline levels and the animal exhibits schizophrenic behavior.

21. A transgenic nonhuman animal according to claim 20 wherein the transgenic nonhuman animal is a mammal.

22. A transgenic nonhuman animal according to claim 20 wherein the one or more alterations comprises substitution of a promoter having a higher rate of expression than the native promoter of the gene.

23. A transgenic nonhuman animal according to claim 22 wherein the promoter is an inducible promoter.

24. A transgenic nonhuman knockout animal whose genome comprises a homozygous disruption in one or more genes selected from the group consisting of those disclosed in Table 1 wherein said homozygous disruption prevents the expression of the gene, and wherein said homozygous disruption results in the transgenic knockout animal exhibiting decreased expression levels of the one or more genes as compared to a wild-type animal.

25. A method of screening for a therapeutic agent that modulates symptoms of schizophrenia comprising administering a candidate compound to a transgenic nonhuman animal according to claim 18 and determining the effect of the compound on symptoms associated with schizophrenia.

26. A method of screening for a therapeutic agent that modulates symptoms of schizophrenia comprising combining a candidate compound with a transgenic nonhuman animal according to claim 20 and determining the effect of the compound on symptoms associated with schizophrenia.

27. A method of screening for a therapeutic agent that modulates symptoms of schizophrenia comprising combining a candidate compound with a transgenic nonhuman animal according to claim 24 and determining the effect of the compound on symptoms associated with schizophrenia.

28. A method of screening for a compound useful in the treatment of schizophrenia comprising operatively linking a reporter gene which expresses a detectable protein to a regulatory sequence for a gene selected from the group consisting of those disclosed in Table 1 to produce a reporter construct; transfecting a cell with the reporter construct; exposing the transfected cell to a test compound; and comparing the level of expression of the reporter gene after exposure to the test compound to the level of expression before exposure to the test compound, wherein

- 62 -

a lower level of expression after exposure is indicative of a compound useful for the treatment of schizophrenia.

29. A method for treating schizophrenia in a host comprising lowering expression of a gene selected from the group consisting of those disclosed in Table 1 by administering one or more RNAi molecules designed to inhibit the expression of said gene .

30. A method for treating schizophrenia in a host according to claim 29 wherein the host is human.

PUB-NO: WO2004053157A2
DOCUMENT-IDENTIFIER: WO 2004053157 A2
TITLE: METHODS FOR DIAGNOSING AND
TREATING SCHIZOPHRENIA
PUBN-DATE: June 24, 2004

INVENTOR-INFORMATION:

NAME	COUNTRY
BUXTON, FRANCIS PAUL	US
CARPENTER, WILLIAM TWITT ^w ?	US
ROBERTS, ROSALINDA CUSID ^w ?	US
TAMMINGA, CAROL ANN	US

ASSIGNEE-INFORMATION:

NAME	COUNTRY
NOVARTIS AG	CH
NOVARTIS PHARMA GMBH	AT
UNIV MARYLAND	US
BUXTON FRANCIS PAUL	US
CARPENTER WILLIAM TWITTY	US
ROBERTS ROSALINDA CUSIDO	US
TAMMINGA CAROL ANN	US

APPL-NO: EP00314089

APPL-DATE: December 11, 2003

PRIORITY-DATA: US43285302P (December 12, 2002)

INT-CL (IPC) : C12Q001/68 , A01K067/027 ,
A61K038/00 , A61K039/00 ,
A61K048/00

EUR-CL (EPC) : C12Q001/68

ABSTRACT:

CHG DATE=20040821 STATUS=O>The genes encoding SCYA2, GADD45B, S100A8, CDKN1A, IL1RL1, TGM2, MAFF, SERPINA3, GRO1, CD14, KIAA1075, CHI3L1, SERPINH1, MT1X, KIAA0620, TIMP1, NUMA1, DDIT3 and TOB2, are upregulated in the anterior cingulate of schizophrenic patients compared to normal patients and as such are useful drug targets for schizophrenia. Methods of screening, diagnosing and treating schizophrenia based on these genes are provided. Transgenic nonhuman animals having increased copy number or increased expression levels of these genes are also provided. The transgenic nonhuman animals are used in methods for screening for potential therapeutic agents.